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The Antioxidant Status of Inflammatory Bowel Disease Patients 	 Abstract 
1. 	Abstract 
Introduction 
Free radical production may play an important pathogenic role in chronic inflammatory 
conditions, such as inflammatory bowel disease (IBD). Protective mechanisms against 
these agents, such as the antioxidant vitamins A, C and E may therefore be important in 
the control ofthe inflammatory process, and may have a therapeutic role in the disease. 
Methods 
100 consecutive IBD patients, attending the outpatient clinic at Groote Schuur Hospital 
were assessed regarding disease characteristics and activity, and nutritional and 
antioxidant vitamin status. This group comprised 56 patients with Crohn's disease (CD), 
and 44 with ulcerative colitis (UC). Results were evaluated in comparison to a group of 
44 normal healthy controls. In order to evaluate the effect of antioxidant therapy on 
disease relapse rates, 23 CD patients were, then randomised to receive either antioxidant 
vitamin supplement or placebo and monitored for a period ofsix months. 
Results 
Despite adequate intakes, serum concentrations of vitamins C, E and retinol were 
significantly lower than control values, whereas ~-carotene levels were similar. The 
vitamin levels in CD and UC were similar. In IBD patients, age, smoking, nutritional 
status and medication did not appear to effect the serum concentrations of the vitamins. 
Active inflammation was associated with significant reduction of vitamin C and retinol 
levels and levels of a-tocopherol appeared to relate to the extent and duration of disease 
in UC patients. Retinol and ~-carotene on the other hand, were low in both UC and CD 
patients with short duration of disease, and tended to increase with prolonged duration. In 
CD patients, recent relapses were associated with higher a-tocopherol levels while for 
UC, a similar phenomenon was shown for retinol. Antioxidant vitamin supplementation, 
r 
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with 100% of the RDA for vitamins A and E, did not influence disease relapse rates or 
quality of life. 
Conclusion 
Serum levels of the antioxidant vitamins A, C and E are low in patients with IBD. The 
reasons for the depleted levels appear multifactorial with disease extent (a.-tocopherol), 
and active inflammation (vitamin C and retinol) playing a significant role. We were 
unable to demonstrate a therapeutic role for vitamin A and E supplementation in the 
maintenance ofremission in CD. 
17 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
The Antioxidant Status of Inflammatory Bowel Disease Patients Literature review 
2. Literature Review 
Part 1: Inflammatory Bowel Disease 
2.1.1 Introduction 
Inflammatory bowel disease (IBD) is a tenn used to describe two diseases, ulcerative 
colitis (UC) and Crohn's disease (CD). They are both chronic inflammatory 
conditions of uncertain aetiology affecting the gastrointestinal tract, with different 
clinical, endoscopic and histological characteristics. UC is mainly confined to the 
mucosa and submucosa, while in CD, the inflammation may extend through the 
intestinal wall from the mucosa to the serosa (transmural). UC is confined to the 
large bowel, whereas CD can occur in any area of the gastrointestinal tract, from the 
mouth to the anus. I -) Often a clear distinction between the two diseases may be 
difficult, and the tenn "indetenninate colitis" is then used. I 
Although the diseases particularly affect the gut, the systemic nature of the 
conditions is evidenced by the extra-intestinal manifestiations including arthritis, skin 
conditions (erythema nodosum, pyodenna gangrenosum), eye problems (uveitis, 
iritis), and involvement of the liver (sclerosing cholangitis). Both diseases follow a 
relapsing and remitting course, and recurrence rates of approximately 70% per 
annum can be expected. 1 
2.1.2 Ulcerative colitis 
The main symptom of UC is diarrhoea, which is often associated with blood in the 
stool. Increased frequency of bowel movements, with the feeling of incomplete 
evacuation (tenesmis), is common. Other symptoms include fever and abdominal 
pain. 1 
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2.1.2.1 Complications of UC 
Complications that occur in DC include haemorrhage, toxic megacolon and 
perforation. There is also increased incidence of carcinoma of the colon in patients 
with long standing disease. I 
2.1.3 Crohn's disease 
CD is often a more complex and difficult disease to manage than DC, mainly 
because of the diversity of its location (Table 1), and it~ associated complications. 
Area affected % of patients at 
presentation 
Ileum and Caecum 40 
Small intestine only 30 
Colon only 25 
Mouthltongue/oesophagus/stomachl duodenum 5 
Table 1: Disease distribution in CD1 
The main symptoms of CD are diarrhoea, abdominal pain and weight IOSS.I.4 Patients 
with tenninal ileal disease or who have had tenninal ileal resections may have fat 
malabsorption and steatorrhoeal ,5,6 and may also develop vitamin BJ2 deficiency.7.s 
2.1"3,, 1 Complications of Crohn's disease 
Complications ofCD include obstruction, fistulae, abscesses and peri anal disease. l 
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2.1.4 Epidemiology 
The incidence and prevalence ofCD and UC varies in different geographical regions. 
The incidence oflBD is higher in Jews than non-Jews (Table 2). In the United States 
the incidence seems to be higher in the white popUlation than the black population. 
However this seems to be changing, with more black people being diagnosed with 
•
9IBD.1
The incidence of IBD may be higher in women, by as much as 30%.1 The peak age 
of onset for both UC and CD is between the ages of 15 and 25 years. Another, 
smaller peak also seems to occur between the ages of 55 and 65 years.1 
FACTOR 
{ 
UC CD 
Incidence (per 100,000) 2-10 1-6 
Prevalence (per 100,000) 35-100 
-' 
10-100 
Racial Incidence High in whites High in whites 
Ethnic Incidence High in Jews High in Jews 
Sex Slight female 
preponderance 
Slight female 
preponderance 
Age at onset 15-25 
155-65 
15-25 
155-65 
Smoking Fewer smokers than 
expected 
More smokers than 
expected 
Table 2: Epidemiology of 1601 
The prevalence of IBD continues to increase. However, latest data shows that the 
incidence of IBD worldwide is around 201100000/year. The prevalence of CD, 
however, has been reported to be around 1001100000 in the developed world.lO Even 
though this prevalence may seem small, the cost of the disease is high. In a study 
20 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
The Antioxidant Status of Inflammatory Bowel Disease Patients Literature review 
undertaken in Sweden it was found that in 1994, the total cost of CD calculated from 
hospital admissions, ambulatory care, drugs, sickness leave and early retirement was 
US $43.1 million. Two percent of all patients were responsible for 10% of the total 
admissions during 1994. This finding was similar to findings in the USA and the UK. 
Only 6% of the total cost (US $2.6 million) was from drugs, and morbidity caused 
more than two-thirds (71 %) of the total costs. \0 A recent study has reported that the 
average cost of care for CD is approximately $12,500 per patient. 11 Furthermore, 
20% of the cases of CD account for 80% of the total cost of the disease, generally 
due to hospitalisation, with an average cost of $37,000 per hospitalised patient. 11 
This highlights the need for efficient, cost effective patient care and treatment, in 
order to keep patients in remission and out of hospital. 
2.1.5 Aetiology of IBD 
The aetiology of IBD remains unknown, however a variety of factors have been 
reported to be associated with the disease. 
2.1.5.1 Genetic Factors 
There seems to be an ethnic and/or familial predisposition to IBD, and therefore, 
genetic traits may playa role in the pathogenesis of mD. Family and twin studies 
have shown that between 10-20% of patients have another first-degree member of 
the family affected, and 41 % of identical twins are affected.12 Candidate gene studies 
have reported associations with genes for tumour necrosis factor (TNF) and other 
pro inflammatory cytokines. Furthermore, genome wide linkage studies have 
identified potential susceptibility loci on a number of different chromosomes, with 
chromosomes 12 and 16\3,14 repeatedly identified. These two susceptibility loci have 
been termed the IBD1 and IBD2 "genes".15 
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2.1.5.2 Environmental factors 
Smoking 
Smoking has been shown to be beneficial in UC and detrimental in CD,13,16 with 
current smokers being more prone to relapse,16,17 and surgery. 18,19 The reason for this 
association is not clear, but may result from the adverse vascular effects of smoking 
(CD),13 and possibly the effects ofnicotine (UC).2°.21 
Diet 
Although no specific foods have been linked conclusively to IBD,13 dietary factors 
may have a primary effect in predisposed patients, or may act together with other 
environmental factors22 in the development offfiD. 
Increased carbohydrate intake in patients with ffiD has been reported.23 This 
however, may be due to patients avoiding fibrous foods22-26 because of the risk of 
obstruction, and therefore consuming relatively great~r amounts of refined 
carbohydrates and sucrose.16,22,26-28 
However, fibre may be protective against ffiD22 due to the production of short chain 
fatty acids (SCF As), during anaerobic fermentation in the intestine. These SCF As, 
especially butyrate, provide a substantial energy source for the colonocyte,29 and 
have a proliferative effect on ileocolonic epithelia. 30 Deficiency of SCF As, and a 
decreased capacity to oxidise SCFAs have been demonstrated in UC/ I and SCFA 
enemas have been reported to be beneficial in patients with distal colitis.31 
Protein intake has been found to be increased in some studies,26,32 while other studies 
have reported no significant findings.22 Furthermore, UC patients may have an 
increased consumption of fat in the pre-illness period, the relevance of which is 
uncertai~ at present. 22 . 
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Vitamins and minerals 
A study by Reif et aI, reported that increased consumption of vitamin A precursors, 
and calcium in the pre-illness diet was positively associated with increased risk for 
IBD,22 while other vitamins such as various B vitamins showed no clear 
association.24 Magnesium and vitamin C intake showed a negative association with 
the risk for IBD, while consumption ofpotassium showed a negative association only 
E35with the risk of CD.22 Furthermore, vitamin A,33-36 and C37,38 serum 
concentrations have been reported to be decreased in IBD patients. 
Total caloric intake 
Total energy intake in IBD may be high or similar to controls, paticularly, but not 
exclusively, in the pre-morbid diet, and in those in remission.23,26,32 Despite this, the 
prevalence of malnutrition in IBD is high, indicating that other factors, such as 
malabsorption, and the metabolic response to inflammation, stress and medications 
are important in determining the nutritional state ofpatients.32 
2.1.5.3 Microbial agents 
No pathogen has been proven to be a transmittable agent that causes IBD.13 
However, bacterial species including Escherichia coli, and Staphylococcus albus and 
aureus may be present in a large proportion of IBD cases.39 Association with M 
paratuberculosis has been reported, but a direct aetiological relationship has not been 
established. 13 ,16,40 This may be the result of secondary invasion of a previously 
damaged mucosa.40 
An association between the pathogenesis of CD and measles virus exposure has also 
been reported. 13,41,42 
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2.1.5.4 Immunology 
There is good evidence that UC and CD are autoimmune disorders. Mucosal T cells 
from children with CD exhibit a hyperactive response to interleukin (IL-) 2. This 
hyper-reactivity was independent of clinical activity, disease location, disease 
duration and treatment, and was found even in areas free of inflammation.43 In UC 
mucosal T cells are particularly susceptible to fas-mediated apoptosis, a physiologic 
process of cell death, suggesting that fas-mediated apoptosis may be important in UC 
pathogenesis.13 Furthermore, mucosal mononuclear cells from UC produce 
autoantibodies against epithelial cell-derived isoforms of tropomyosin. 13 Long­
lasting clinical remissions have also occurred in CD patients who have undergone 
allogenic bone marrrow transplantations.13 
Furthermore, the gut immune response in CD seems to differ from that in UC, and in 
normals. The normal gut is in a constant state of immune activation in response to 
luminal antigen. This is however of the Th2 ty e, characterised by the production of 
cytokines IL-4, IL-5 and IL-I 0 resulting in a non-inflammatory, humoural immunity 
with the production of IgA antibodies.44,45 The mucosal inflammatory response in 
CD is, on the other hand, associated with the production of the cytokines TNF, 
interferon gamma (IFNy), and IL-2 resulting in an inflammatory cell mediated (Thl) 
immune response.44,45 Interestingly, the cytokine profile in UC seems to be of the 
Th2 type.44 
Recognition of the importance of the Thl response in CD has lead to the use of 
specific monoclonal antibodies directed against TNF (Infliximab®), which have been 
shown to be efficacious in the treatment of steroid refractory CD, and in the 
treatment of fistulas. 13,29.46-48 IL-IO results in the down regulation of TNF and has 
been reported to be efficacious in active CD,47.48 and drugs such as thalidomide, 
which also have anti-TNF affects, have been found to be useful in the management 
ofCD.47 
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Transcription factors 
Nuclear Factor KE (NF-KB) is a group of transcription factors which playa major 
role in the regulation ofpro-inflammatory cytokine production. The group consists of 
several proteins including NF-KBI, NF-KB2, p65, c-Rel, and RelB, and is found in 
the cytoplasm of most cells as an inactive complex bound to the inhibitory protein, 
inhibitory Td3 (IKB). Activation of the cell with various stimuli, including TNF-a, IL­
I and IL-18, results in phosphorylation of IKE, and the disruption of inactive 
complex, and the release ofNF-KE. NF-Td3 then translocates into the nucleus, binds 
to DNA regulatory sites and initiates transcription of various inflammatory 
cytokines46,48,49,50 including IL-I, IL-6 and TNF_a,46,47,50 as well as essential proteins 
for antigen presentation (Figure I). 
NF-Td3 expression has been shown to be increased in IBD, and CD has been 
associated with increased levels of Thl-type cytokines (eg. TNF-a, IL-2, and IFNy), 
the promoters of which are regulated by the NF-KB pathway.50 Control of NF-KB 
activity is therefore an attractive option for the management of IBD. Many of the 
drugs currently used in IBD have been shown to directly affect NF-KB activation.50 
Glucocorticosteroids repress NF-KE activity by inducing IKB production, and 5­
arninosalisylates (5-ASA) compounds and immunosuppresive agents (azathioprine 
[AZA], 6-mercaptopurine [6-MP] and cyclosporin) inhibit NF-KB activation. 
Antioxidants have also been reported to suppress NF-KB activation, possibly by 
inhibiting the disruption ofthe inactive complex with lKE.50 
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Figure 1: Interaction between NF-KB, antioxidants and pro-innammatory cytokines. 

NF-KB signal induction by TNF-a, IL-1, IL-1B via the TNF receptor associated factor (TRAF) and 

the TNF receptor associated death domaine (TRADD) resulting in phosphorylation of the NF-KB 

IKB complex and the release of cytosolic NF-KB. NF-KlJ translocates to the nucleus, binding to its 

target DNA sequences. Steroids directly induce the production ofIKB, and antioxidants, 

immunosuppressants and 5..ASA inhibit the activation of NF-KlJ. 
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I Degraded 
Steroids 
Apoptosis 
Apoptosis (programmed cell death) is an important immune system mechanism that 
controls the overall size of cell clones which undergo expansion in response to 
antigenic stimuli.51 It may also be involved in epithelial injury, and has been reported 
to playa role in the pathogenesis of IBD.52 In fact mesalamine's beneficial effect in 
IBD has been reported to also relate to its involvement in the attenuation of peroxy­
nitrite induced cell injury and apoptosis.53 
Fas-ligand (Fas-L) is a transmembrane protein which belongs to the TNF receptor 
family. The Fas-L system induces programmed cell death and has been reported to 
aid in the colonic depletion of T lymphocytes to suppress autoimmune reactions.51 
Fas-L is expressed on the surface of cytotoxic T lymphocytes (CTLs), where it acts 
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as an effector for apoptosis. Fas-L transcripts are highly expressed in active UC, and 
Fas-L messenger ribonucleic acid (RNA) is strongly expressed in CD3 T 
lymphyocytes infiltrating the lamina propria of affected mucosa only. Furthermore, 
Fas-L may also have an indirect role in the progression of mucosal lesions in UC via 
the increased production and secretion of IL-8 from the colonic epithelium, which 
results in the promotion, migration and activation oflymphocytes and neutrophils.51 
In CD, however, although cells for the lamina propria do express Fas on the cell 
surface, they seem to be less sensitive to Fas antigen cross-linking compared with 
healthy individuals, and decreased apoptosis compared to controls has been noted. 54 
This may be due to increased concentration of antiapoptotic proteins such as Bcl-2. 
IL-2 induces Bcl-2 via a protein on the IL-2 molecule which serves as a signalling 
component of the receptor for IL-2, IL-4, IL-7 and IL-15. It is therefore up-regulated 
in cells on stimulation of various cytokines, and may be the mechanism used by· 
cytokines to promote cellular survival. The increased levels of Bc1-2 found in the 
inflamed tissue of CD patients may be due to the increased exposure of these cells to 
various cytokines, and therefore, the increased levels of Bcl-2 are probably 
secondary to the inflammation that occurs in CD. 54 Furthennore, IL-6 may also play 
a role in the inflammation that occurs in CD, possibly due to resistance of mucosal T 
cells against apoptdsis. IL-6 can bind to cells which don't have an IL-6 receptor 
when it fonns a complex with soluble IL-6R (SIL-6R). In a study which blocked the 
IL-6 trans signalling, T-cell apoptosis was increased. Since IL-6 is increased in the 
lamina propria of CD patients compared to controls, and since the· increased 
production of IL-6 in CD was associated with increased production of SIL-6R, the 
IL-6-SIL-6R complex may contribute to the perpetuation of chronic intestinal 
inflammation.55 
Reactive metabolites 
Reactive oxygen species and nitrogen metabolites are significantly raised in the 
circulation and in the inflamed mucosa13,56,57 in both CD and UC compared to 
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controls. 13,57 Neutrophils,4\ ,42-50,56-60 eosinophils, monocytes,50,56,58 macrophages,56 
and phagocytic leukocytes,56,61 produce and release large amounts ofreactive oxygen 
metabolites (ROMs) which are toxic56 and can cause tissue injury and dysfunction. 
They may also further perpetuate inflammation.62 Furthennore, neutrophil derived 
oxidants may also damage the epithelium and mucosal interstitium: indirectly, by 
changing the protease/anti-protease balance in the intestine.56,63 These factors are 
discussed further in part 3. 
Inflamed colons produce increased amounts of reactive oxygen species when 
compared to non-inflamed colons.56-58,62,63 Furthennore, there seems to be decreased 
endogenous intestinal protection against these oxygen-derived radicals.64 The chronic 
gut inflammation that occurs in IBD may relate to an imbalance between pro-oxidant 
and antioxidant mechanisms, leading to the net accumulation of oxidatively modified 
proteins and lipids. 56 
2.1.6 Nutritional Status in IBD 
The various causes ofnutritional deficiency are illustrated in table 3. 
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Reduced food Intake Anorexia 
Fear of eating from abdominal pain 
Restrictive diets without supplementation 
Increased requirements and 
decreased synthesis 
Active Inflammation 
Sepsis 
Enteric Loss of nutrients Exudation from intestinal mucosa 
Interrupted entero-hepatic circulation 
GI blood loss 
Malabsorption Loss of absorptive surface from disease, 
resection or bypass 
Stagnant loop syndrome from strictures, fistulae 
or surgically created blind loops 
Bile Salt deficiency after ileal resection 
Bacterial overgrowth 
Mucosal cell disease 
Lymphangectasia 
Rapid GI transit 
Drug interference Corticosteroids and calcium absorption/protein 
metabolism 
Sulfasalazine and folate absorption/haemolysis 
Cholestyramine and fat-soluble vitamin 
absorption 
28Table 3: Pathogenesis of malnutrition2•
2.1.6.1 Malnutrition 
The prevalence of malnutrition has been reported to be as high as 70-80% in some 
65centers. ,66 In CD without extensive small bowel involvement, weight loss is mainly 
due to a decrease in energy and protein intake,65 however, fat maiabsorption30 and 
carbohydrate malabsorption5 in the form of lactose intolerance, may also occur. 
Decreased protein intake and increased intestinal losses of nitrogen,67 may lead to 
major losses of body protein mass in IBD in a small number of patients. However, 
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low serum albumin concentrations are usually the result of active inflammation 
(negative acute phase response), increased intestinal losses, and maldistribution 
between intravascular and extravascular spaces.67 
Bile acid metabolism may be altered in ileal CD, as well as in patients who have had 
small bowel resections, resulting in steatorrhoea.3o 
Diarrhoea may damage the intestinal villi resulting in decreased lactase activity in 
IBD patients. This often results in incomplete lactose intolerance, so that a small 
amount of lactose may be tolerated.5 
2.1.6.2 Vitamin abnormalities 
A number of serum vitamin level abnormalities have been reported in patients with 
IBD, with reduced levels of vitamin A,34,35 vitamin E, pyridoxine, vitamin BI2 ,7,8 
C34thiamin, riboflavin,35 folate/4,35 biotin,34 ~-carotene,34 and vitamin being 
reported. It should be noted however, that a reduced serum level does not necessarily 
include vitamin deficiencies, and clinical signs of deficiency may only develop in 
severe longstanding disease.35 
Vitamin C 
Decreased serum vitamin C levels in patients with IBD have been reported.7,37,38 
Although the precise mechanism is unclear, dietary deficiency may playa role,7,37 
with reports indicating improved serum levels with increasing dietary intake.7 
Vitamin C serum levels seem to be lo~er in those with colonic disease.38,68 Since 
vitamin C is a powerful antioxidant, and may be the first line of defence against 
oxidant damage,69,70 the low levels may be the result of increased utilisation due to 
the relatively low stores of endogenous antioxidants in the colon, in comparison to 
the levels ofROMs.38,71 
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Vitamin A 
Low serum vitamin A has been described in CD, but these low levels have not been 
clearly associated with any clinical signs of vitamin A deficiency.34 However, in a 
study of 137 CD patients it was found that serum retinol concentrations were normal, 
despite 34% of the sample consuming less than 100% of the RDA.33 Furthermore, 
low serum carotene levels were reported, and were not related to low dietary intakes, 
or to active CD, and were thought to rather be related to the presence of 
steatorrhoea.33 Studies have also shown that vitamin A is absorbed normally in mD 
patients,72,73 and that the low serum carotene level does not indicate that the patients 
are at risk of developing vitamin A deficiency.33 The low vitamin A levels may also 
be due to decreased retinol binding protein (RBP) concentrations as a result of 
increased protein catabolism or inadequate intakes.33,73 
Vitamin E 
Serum concentrations of vitamin E have been reported to be decreased in mD.34,35.74 
However, when cholesterol was tested it was found that the vitamin E to cholesterol 
ratio was normal indicating that the low circulating vitamin E levels may be due to 
hypocholesterolaemia.34.74 
Folate 
Between 10 and 65% ofpatients with mD are likely to have decreased serum and red 
blood cell folate (RBCF) levels,' which may lead to anaemia.3o Salazopyrin (SZP) 
may also lead to a folate deficiency.2~2s 
Vitamin 8 12 
Low serum concentrations ofvitarnin B12 occur in 10-16% of CD patients7 and may 
lead to anaemia.3o This is usually associated with resection or disease of the terminal 
ileum/'S and many patients require supplementation with vitamin B12 post ileal 
resection. 
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2.1.6.3 Mineral deficiencies 
Various mineral deficiencies have been found to occur in liD including calcium,7 
magnesium,7,73 iron,7,66 zinc,73 copper,75,76 and selenium.76 
Calcium 
Low serum calcium levels have been reported in approximately 20% of patients. 
Calcium depletion may occur as a result of vitamin D deficiency, inadequate intake 
especially for those on a low lactose or lactose-free diets, malabsorption, steatorrhoea 
and corticosteroid therapy.7 
Magnesium 
Fistulas, malabsorption, small bowel resection and any other condition that results in 
the abnormal loss ofintestinal contents including diarrhoea or tube suction, as well as 
prolonged periods of inadequate oral intake, intravenous fluid supplementation 
without magnesium, corticosteroid therapy/ increased intestinal losses and 
malabsorption,7,73 can result in depletion. 
Iron 
Twenty five to fifty percent of patients with CD, and up to two thirds of DC patients 
may have an iron deficiency,66 usually as a consequence of chronic blood loss in the 
gut. This, together with folate and vitamin B12 deficiencies, is the major cause of 
anaemia in IBD. 7 
Zinc 
Zinc status in liD is controversial,75,76 but may be of concern in patients with severe 
diarrhoea or enteric fistulae. 73 Zinc deficiency may occur as a result of 
I 
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malabsorption, increased intestinal or urinary losses, increased requirements 7 or a 
decrease in albumin, the main zinc binding protein.7,73 
Furthermore, in patients with active CD, plasma zmc may decrease due to 
intrahepatic sequestration of circulating meta1.7 Zinc also acts as a cofactor of 
superoxide dismutase, an antioxidant enzyme, which also seems to be reduced in 
IBD. Since oxidant stress may be increased in the inflamed mucosa, zinc 
requirements may increase in order to maintain adequate amounts of this enzyme.75 
Perhaps the high Zinc levels found in some studies, are a result of the zinc being 
mobilised for this purpose.76 
Zinc itself can act as an antioxidant and inhibits the direct oxidation of enzyme 
sulfhydryl groups.60 
Copper 
Serum copper levels have been reported to be elevated in IBD when compared to 
controls.75,76 Excess total tissue copper, may catalyse free radical formation and 
increase the oxidative stress in the mucosa.75,76 
Selenium 
Serum concentrations of selenium may be reduced in IBD. Since selenium has 
known antioxidant properties, its lower level may contribute to inflammation, as well 
as to the increased prevalence ofcancer in IBD.76 
2.1.7 Methods of assessing disease activity in IBD 
Various assessment methods have been developed to assess disease activity in IBD. 
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2.1.7.1 The Crohn's Disease Activity Index 
The CDAI was designed as an objective assessment measure that could give a 
numerical value that would be proportional to severity of illness.77 
The CDAI takes 8 variables into account: frequency of soft/liquid stools, abdominal 
pain, general well being, extraintestinal manifestations (arthritis, erythema nodosum, 
pyoderma gangrenosum, apthous stomatitis, iritis and uveitis, anal fissures and 
abscesses, and fevers), use of opiates or lomotil for diarrhoea, abdominal masses, 
haematocrit, and body weight.77 The index requires a 7-day documentation by the 
patients ofhis or her symptoms.78 
The CDAI, however, does have shortcomings. The predominance of SUbjective 
symptoms such as abdominal pain and general well being may introduce 
inaccuracy.77-79 Furthermore, the medication that is often prescribed in CD may 
influence these subjective complaints. Also, patients with CD who have had a bowel 
resection, especially an ileocaecal resection, often have a higher defaecation rate and 
produce soft stools, even though no active disease is present. The CDAI also does not 
take into account other important objective parameters such as serum albumin level 
and ESR,19 and the only laboratory parameter that is used in the index is that of 
haematocrit, which may be less discriminate than other acute phase reactants80 and 
may not be an adequate measure ofdisease activity.9.81 However, in a study in which 
three indices were compared - a simple clinical index, designed by the authors, 
specifically for the study (scored on a scale of 1-6 with 1 being well and 6 being 
fulminating attack. Clinical parameters used were diarrhoea, pain, systemic 
manifestations and a general feeling of well being), the Van Hees index and the 
CDAI , and it was found that the CDAI was the most sensitive iI:!dicator of an acute 
attack,81 and is the index most often used in clinical trials. 
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2.1.7.2 The Van Hees Index 
The Van Hees index was designed in response to a need for maximally objective, 
reproducible, quantitative manner of assessing disease activity in IBD, especially 
CD.79 It contains nine variables; serum albumin, ESR, body weight related to 
length, abdominal mass, sex, temperature, stool consistency, bowel resection, and 
extraintestinal symptoms related to CD.79 
The Van Hees index may be more objective than the CDAI as it uses parameters 
such as serum albumin and haemoglobin values. It is also less patient-dependent.79 
However, the index may vary according to the inter-laboratory variation in the 
determination of serum albumin79 and complex and time-consuming calculations 
are necessary,81,82 making it less ideal for routine use.79 
2.1.7.3 The Harvey Bradshaw Index 
The Harvey Bradshaw index (HBI) is a simplified form of the CDAI, which 
quantifies the patient's previous 24-hour symptoms.78 It was first developed in 1980, 
as a means of assessing activit  in either CD or UC.78 It is based on 5 items; general 
well being, abdominal pain, the number of liquid stools per day, abdominal mass and 
complications.82 
The HBI has easy calculations, and does not need to be planned in advance82 but is 
heavily biased by the frequency of diarrhoea.9,78 It is however, a useful index in the 
assessment ofpatients with UC. 
The CDAI was selected as the tool for assessment of CD activity in this thesis as it 
has been shown to be widely tested and found to be the best indicator of active 
disease. The HBI will be used to assess clinical disease activity in UC. 
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2.1.7.4 Other indicators for assessing disease activity in IBD 
Laboratory tests reflecting inflammatory activity should provide additional 
infonnation in patient management. They should give an objective assessment of 
disease activity by identifying clinical deterioration not due to active inflammation, 
for example fibrotic intestinal strictures.83 
Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are often used as 
inflammatory markers and indicators of activity in IBD. They are however, not 
specific for IBD.84 The CRP is an acute phase reactant which is sensitive to many 
types of inflammation8! ,83 and has been reported to correlate significantly with 
clinical status in IBD.80,83 Similarly, the ESR is commonly increased in active 
inflammatory disease and is often used as an indication of inflammation. It is 
however, subject to a large number of variables including changes in some serum 
proteins as well as changes to the erythrocyte. ESR has been reported to correlate 
significantly with clinical status in IBD patients.8o 
Since the ESR has been shown to correlate with clinical status in IBD patients, and 
since it is used routinely in our clinic, the ESR will be used as a direct indication of 
inflammation in this study. 
2. 1.7.5 Methods ofassessing quality of life (QOL) in IBD. 
The impact of inflammatory bowel disease on the lives of patients is often not 
reflected by inflammatory markers or extent of disease, as the emotional and social 
problems that occur are not accounted for. 85-87 The chronic nature and morbidity of 
IBD are major factors in the impainnent of QOL in these patients.88 However, the 
disease has such a relapsing-remitting course that the extent to which the QOL is 
affected may vary considerably, both inter-individually and intra-individually.88 
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A combination of generic and disease-specific scales may provide the best approach 
to assessing health related QOL in IBD.85 Some of the more widely used 
questionnaires will be discussed below. 
The Inflammatory Bowel Oisease Questionnaire (IBOQ) 
The IBDQ is a disease-specific scale, which can be administered by either the 
interviewer,87,88 or it can be self-administered.89 The scale has 32 items which are 
grouped into four sections; bowel symptoms, systemic symptoms, emotional factors 
and social factors. 85,86 Each item is scored on a scale of 1 to 785,86 and the total IBDQ 
score may range from 32 - 224. The higher the score, the better the health.85 This 
QOL ~easure is well correlated with disease activity indices for both CD and UC.87 
The Modified IBOQ and the Short-Form IBOQ 
The modified version of the IBDQ is designed for patients with IBD, who are 
"clinically well". It uses 36 items, divided into 5 sections; bowel symptoms, systemic 
symptoms, functional impairment, social impairment and emotional function. 88 
The short-form IBDQ is a simplified version of the IBDQ. It only contains 10 
questions and can be administered in 5 minutes. It has however, not been fully 
validated.88 
The Medical Outcome Survey (MOS) Short Form-36 Health Survey (SF­
36) 
This QOL questionnaire has been validated in many different conditions and in the 
general population,85,89-93 and has good test-retest properties.9o In fact, in a study by 
Brazier et ai, in which the reliability or reproducibility of this questionnaire was 
tested on 1980 people, the maximum mean difference in the dimension score was 0.8 
meaning that a person who scored 70 on one test, may score 71 on re-test.90 The SF­
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36 is a shortened version of 149 health status questions. It consists of 36 items 
grouped into 10 sections; physical function, physical role limitation, mental role 
limitation, social function, mental health, energy and vitality, pain, health perception, 
and change in health. The dimension score is expressed as a value between 0 and 
100, with higher scores showing better health.85 The questionnaire takes only 5 -10 
minutes to fill out,91 can be self-administered,94 is easily understandable95 and 
therefore is highly acceptable to patients.9o It also correlates well with the doctor's 
assessment of the severity of illness.95 Therefore it is practical, and acceptable to the 
popUlation, and is easy to use.90 However, since the questionnaire is not disease 
specific, it should be used as part of a more detailed portfolio of measures to assess 
aspects of a patient's outcome.92 But, the SF-36 is a good measure for detecting 
average group differences or changes over time.93 
Since this questionnaire, has been widely tested, can be easily administered and 
understood, and is a good measure of detecting average group differences, the SF-36 
QOL questionnaire will be used to assess QOL in this study. 
2.1.8 Treatment ofIBD 
2.1.8.1 Drug therapy 
Therapy of IBD is directed towards induction and maintenance of remission, and the 
avoidance ofcomplications. 
Corticosteroids 
Steroids remain the mainstay of therapy in inducing remission in patients with active 
disease, and have been shown to be successful in approximately 70% ofpatients. ,96. 
100 Despite this efficiency in inducing remission, steroids have not been found to be 
of value in maintaining remission?9,96.]OO Side effects from corticosteroids occur 
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often and include moon face, acne, hirsutism, striae, obesity, hypertension, diabetes, 
infection, osteoporosis, osteonecrosis, myopathy and cataracts.29,IOI Nutritionally, 
corticosteroids may inhibit calcium absorption, induce magnesuria and alter protein 
metabolism.73 
Steroids with low systemic bioavailability, such as budesonide, are increasingly 
being used for therapy in IBD,29,46,I02 in order to decrease the risk of bone mineral 
abnormality and osteoporosis,97 as well as other systemic side effects.29,to2 
Aminosalicylates 
The main indication for the use of 5-aminosalicylate (5-ASA) compounds is for the 
maintenance of remission in patients with colonic disease. Sulphasalazine and 
olsalazine require colonic bacterial metabolism in order to release 5-ASA, and are 
therefore only effective in colonic disease. Formulations such as Asacol® and 
Pentasa® release 5-ASA in the small bowel and may also be of value in ileal CD.29,96 
5-ASA may playa direct role in the scavenging of oxidants,lo3-lo8 in particular 
hypochlorous acid (HOCL) that is produced by neutrophils in the inflamed 
colon. lo3,lo6 However, 5-ASA may also act as a pro-oxidant, when the ratio of 5-ASA 
to iron is similar, thereby promoting oxidative degradation of deoxyribose. The tissue 
injury, mainly affecting the stomach, that may be seen with 5-ASA administration 
may be the result of this interaction. lOB 
Immunomodulators 
Azathioprine and 6-Mercaptopurine 
6-MP and AZA are efficacious as steroid sparing agents in both UC and CD 
patients.29,96,109,110 They are useful in the prevention of relapses in patients with 
Crohn's ileocolitis, and in patients with UC who have relapsed despite the use of 5­
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ASA.29,96,97,111 They have also been found to be useful in the management of patients 
with fistulising CD.96,100,109,\ 10 
AZA may also act as an oxidant scavenger. The compound undergoes hepatic 
cleavage releasing 6-MP which contains a thiol group. It is thought that oxidants 
such as HOCL, chloramines, nitric oxide (NO) and peroxide (H202) react with thiols. 
Furthermore, the thiol group on 6-MP may also protect against oxidant cellular 
damage by providing an alternative thiol target for inflammatory oxidants. I 12 
Other Immunomodulators 
Methotrexate and cyclosporin have also been reported to be useful in IBD,29,97,102,1J3 
however, their side effects, including hepatic and renal dysfunction, tend to limit 
their use.96,114 
Antibiotics 
Antibiotics have been shown to be useful in the management of CD. Ciprofloxacin 
has been shown to significantly reduce disease activity, and metronidazole has been 
reported to reduce relapses following surgery.97.115 Metronidazole may also be useful 
in the treatment of fistulising CD.116 
2.1.8.2 Dietary therapy 
Patients should maintain a normal diet as far as possible. However, in certain 
instances specialised diets may be required. Patients with obstructive disease may 
benefit from low soluble fibre diets, whereas high insoluble fibre diets may benefit 
patients with colonic disease.22,29 Fibre, is anaerobically fermented in the intestine to 
produce SCF As; acetate, proprionate and butyrate. Butyrate is the preferred energy 
substrate of the colonocyte. It also has proliferative effects on ileocolonic epithelia 
together with the other SCF As. In this way a high fibre diet may be beneficial in 
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colonic disease,30 and soluble fibre may also be beneficial in obstructive disease as 
SCF As are produced, but, the risk ofobstruction is reduced. 
Parenteral nutrition 
Since the necessity for "bowel rest" in the management of active IBD was 
questioned,73,117-120 and due to the importance ofluminal nutrients in the maintenance 
and integrity of the bowel, early enteral feeding is now generally advocated. 
However, in patients with obstructive disease, or severe fistulising disease,120 total 
parenteral nutrition (TPN) may be required as supportive nutritional therapy.74 
Similarly, for patients "with short bowel syndrome, home parenteral nutrition (HPN) 
may be essentia1.74, 118,120,121 
Enteral nutrition 
Randomised trials have shown that both elemental diets, and polymeric diets are 
effective in achieving remission in CD patients,73,121,122 and have few side 
effects. 123,124 Elemental diets reduce intestinal inflammation and protein loss, while 
restoring the intestinal mucosal barrier functionl25.126 and in adolescents they may 
reverse growth failure and increase lean body mass. 126 
The manner in which dietary therapies have their effects is still not entirely clear. 
Improving nutritional status may assist the healing process and elemental diets, by 
avoiding antigenic stimuli in the gut, may influence the immune response to down 
regulate. Also, the provision of essential nutrients such as glutamine, which 
influences the metabolism and differentiation of epithelial tissue, might enhance the 
repair of the diseased intestinal mucosa.119 
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Fish oil 
Fish oil contains high concentrations of eicosapentaenoic acid and docosahexaenoic 
acid (n3-fatty acids). These fatty acids compete with arachidonic acid (n6-fatty 
acids), resulting in the production of prostaglandins and leukotrienes which are less 
inflammatory.127 Although fish oil has been shown to decrease leukotrine B4, a pro­
inflammatory factor in IBD, the clinical response in active IBD has been 
disappointing.29,127 Beluzzi et aI, however, showed that an enteric-coated fish oil 
preparation was effective in reducing the rate of relapse in CD128 (Figure i 29). 
Figure 2: Interaction be ween n6-fatty acids and n3-fatty acids. 

Ingestion of n6-fatty acids results in the metabolism of arachidonic acid and the production of 

inflammatory prostaglandins (of the 2 series) and leukotrienes (of the 4 series) such as 

leukotriene 84. Ingestion of large amounts of n3-fatty acids, however, alters the pathway, so that 

eicosapentaenoic acid and docosahexaenoic acid compete with arachidonic acid for the pathway, 

and produce prostaglandins of the 1 or 3 series and leukotrienes of the 5 series, which are less 

pro-inflammatory. 
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Short-chain fatty acids 
Deficiency of SCF As has been implicated in DC and in addition, DC patient's 
colonocytes may have a reduced capacity to oxidise SCF As. Furthermore, SCF A 
enemas have been reported to be beneficial in treating distal disease.29 
2.1.8.3 Surgery 
Surgery, with total colectomy, may be considered curative in DC, and is indicated in 
patients with refractory disease, or those considered to be at high risk of 
complications such as malignancy. In CD however, surgery is generally restricted to 
complications, such as obstructive disease and fistulisation. S 
Ileal resections may result in fat malabsorption and steatorrhoea, and inadequate 
vitamin A, D, E, K and B12 absorption can occur. 130 
Part 2: Dietary and Nutritional Assessment 
2.2.1 Introduction 
There are various methods of assessing dietary intake, and each has its advantages 
and disadvantages. All the methods, however, rely on information given by the 
subjects themselves.13t Important sources of errors in all dietary surveys include 
inaccurate recall of foods eaten and incorrect estimation of portion sizes,132 Reported 
current dietary habits may also be more representative of previous dietary habits, 
which may have since changed due to gastrointestinal disorders. SUbjects may also 
be tempted to report a diet which they consider "prudent", The limitations of dietary 
assessment by recall should therefore be appreciated. 13 ! 
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• 

Dietary assessment methods include dietary histories, dietary records, dietary recalls, 
and food frequencies. Each ofthese will be discussed briefly. 
2.2.2.1 Dietary history 
This method of dietary assessment involves the questioning of a subject about a 
typical day's eating pattern. Each meal is discussed in tum to find out which foods 
were used, and in what proportions. Other alternatives, which may have been used on 
other days of the week, and any irregUlarities in the eating pattern are established, so 
that a menu for 7 days to a month can be calculated. This type of interview usually 
lasts for 1-1.5 hours l31 and has been found to be an "adequately reliable" method of 
dietary assessment. 133 
2.2.2.2 Dietary records 
The subject weighs and records bef re eating and again after eating. The total value 
-

of the food that was eaten is then recorded in ajoumal. The subject must therefore be 
taught the correct method of food weighing, and instructed not to change their 
habitual diet. Any composite recipes should also be written down, as well as type of 
food that is eaten, and the method of preparation in order for intake to be analysed 
correctly.13I Therefore, this method is time-consuming and needs a literate subject 
with a large amount of patience. 131 ,133 
2.2.2.3 Dietary recall 
Dietary recall involves an interview in which the actual food intake of the subject for 
the immediate 24-48 hours is recalled. Food quantities are assessed by the use of 
household measures; food models, and/or photographs.13I However, it has been 
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reported that this method leads to under-reporting of normal intake, and therefore a 
single 24 hour recall cannot be used to accurately assess an individual's intake.133 
2.2.2.4 Food frequency 
The food frequency method estimates how frequently certain foods are eaten during a 
particular period of time. To estimate the nutrient intake, food frequency scores for 
individual items are multiplied by the nutrient content of the local standard portion or 
estimated portion size.13I A semi-quantitative food frequency questionnaire can be 
used in which portion sizes are assessed. During this questionnaire the subjects are 
asked to report their current intakes of various foods according to the frequency of 
consumption, as well as the typical serving size that is consumed of the particular 
food. Food models, measuring cups, and spoons are used throughout the interview in 
order to assess usual intake more accurately.134 This method may be of greatest use 
in epidemiological studies.132 It is cheap, quick and simple to use. 132 ,134 The 
frequency form can easily be filled out by the subjects themselves,132 however, to 
establish the quantities of the food eaten, a trained investigator is needed. 
Since this method of assessment relies on the subject's ability to recall what they 
have eaten, and omissions may be made, the estimates of intake may be lower than 
those that could be obtained from a dietary record method.134 Furthermore, the 
relative validity of the food frequency questionnaire estimating a limited number of 
dietary components is, in general, better than the relative validity of these type of 
questionnaires trying to estimate the whole diet. 131 
Accuracy of the Food Frequency questionnaire for the analysis of 
antioxidant vitamins 
In a study by Russell-Briefel et aI, in which three dietary methods (the 24 hour recall, 
the three-day food record and a food frequency questionnaire) were compared for 
their ability to evaluate vitamin A intake, it was found that the food frequency 
questionnaire method produced vitamin A results more similar to the 3-day record 
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(which is considered the most reliable method of the three), than the 24-hour 
recall. 135 Similarly, in a previous study in our clinic where we assessed the nutrient 
intake of our patients with both the 24 hour recall and the semiquantitative food 
frequency questionnaire, we found that the 24 hour recall seemed to underestimate 
intake in these patients.9 Since the food frequency questionnaire covers the longest 
period of time and usual intake is collected, the intra-individual variation is 
decreased. And therefore, the food frequency questionnaire may be the preferable 
method for the estimation of vitamin A intake in individuals. Furthennore, the 
reliability of food frequency questionnaires has been reported to be high.135 
Similarly, other investigators have found that a food frequency questionnaire was a 
valid instrument for assessing the intakes of carotenoids and a-tocopherol,136-139 and 
this nutritional assessment measure has been used in a number of trials assessing 
intake of antioxidant vitamins including the Scottish heart health study,140 the Alpha­
tocopherol Beta-carotene (ATBC) Cancer Prevention study,141 and a study by 
Persson et aI, looking at the effect ofdiet in IBD.142 
Therefore, since the food frequency questionnaire has been shown to be a valid 
instrument for assessing intake of antioxidant vitamins,136-139 is cheap, quick and 
simple to use,132,134 is the method that may be of greatest use in epidemiological 
studies,133 and has been used in similar studies to ours,140-142 a semi-quantitative food 
frequency questionnaire will be used in this study. 
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2.2.3 Nutritional assessment 

2.2.3.1 Anthropometry 
Anthropometric assessment of nutritional status has been shown to be a simple, 
reproducible method of detecting patients at risk from malnutrition,66 either from 
over or undernutrition. 
The nutritional status of an adult is easily indicated by relating their weight to their 
height. The body mass index (BMI) relates the weight to the square of the height, an 
estimate of the body surface area (BMI =weightlheight2).5 By convention a BMI of 
greater than 30 is obese, 25-30 is overweight, 18.5-25 is normal, 16.0-18.4 is 
undernutrition and a BMI below 16 is severe malnutrition.9 
Another simple method of identifying malnourished patients is the measurement of 
the mid arm circumference. Mid arm circumference (MAC) measurements correlate 
positively with body weight in patients with CD.143 Tricep skinfold thicknesses 
(TSF) however, may be a useful assessment measure of fat stores, particularly in 
large scale population studies. l44 Apart from the lack of need for accurate weight and 
height scales, the MAC does not offer any real advantage over the BMI. 
For the purposes of our study, the BMI, MAC, and TSF will be used as an indication 
of nutritional status. 
2.2.3.2 Laboratory measurements 
Serum albumin levels and total protein concentrations correlate poorly with lean 
body mass. 145 They also tend to decrease rapidly during inflammation (negative acute 
phase response), and may also be lost from the bowel as a result of inflammatory 
exudation (protein-losing enteropathy). Therefore, albumin is not a good indicator of 
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t 't' I 146147 h I I I . .nu n JOna status,' ow ever ow eve s may compromIse the healIng process, and 
therefore may reflect a poor prognostic sign. 
Part 3: Free Radicals and Antioxidants 
2.3.1 Introduction 
2.3. 1.1 Free Radicals 
Free radicals are compounds with an unpaired electron or proton, which are unstable 
and react readily with other molecules, forming new free radicals.3 They can be 
formed in biological systems in various ways, and are often released by activated 
neutrophils,41,42-50,56-60 eosinophils, monocytes,50,56,58 and macrophages.56 Organic 
compounds may be cleaved and each of the new molecules keeps one electron from 
the original pair, or a receptor molecule may capture an electron. Furthermore, a 
chain reaction can occur during the formation of free radicals in polyunsaturated fatty 
acids (PDF A), in which the resulting fatty acid radicals can react spontaneously with 
oxygen to form a fatty acid peroxyl radical. This may then abstract hydrogen atoms 
to form hydroperoxide and new fatty acid radicals, thus propagating the processJ48 
(Figure 3148). 
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Figure 3: The free radical chain reaction that occurs during lipid peroxidation. 

An initiator radical forms new free radicals in the lipid membranes and hydroperoxide is 

generated. If two free radicals join together, they may share the extra electron or proton, thereby 

terminating the chain reaction 

Initiation: 
Inititator! fR\ + 02 ~ ROO' 
Radical ~
RepresentsPropagation: the lipid 
L" + 02 ~LOO' 
LOO . + LH _-"PI +L' 
GeneratedTermination: 
Hydroperoxide 
2LOO' -----""nonradical products 
Oxygen containing free radicals (e.g. hydroxyl radical, superoxide anion radical, 
H202, singlet oxygen, HOeL, NO radical and peroxynitrite) are highly reactive, and 
are capable of damaging molecules such as DNA, protein, carbohydrates and lipids 
in the membranes of cells and on the nucleus. The destructive chain reaction that is 
started by free radicals can be br ken by antioxidants, which are able to convert 
harmful free radicals into harmless derivativesl49 (Figure 4). 
Figure 4: Free radical propagation and antioxidant interaction. 

Free radical R ., produced from activated neutrophils, for example, tries to propagate 

the free radical but passes the extra electron/proton to the antioxidant X, which passes 

the free proton/electron to NADH, thereby ending the chain reaction. 

Activated 
neutrophils/eosinophilsl 
monocytes/macrophages 
2.3.1.2 Antioxidants 
A broad definition of an antioxidant is "any substance that, when present at low 
concentrations compared with those of an oxidisable substrate, significantly delays or 
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inhibits oxidation of the substrate". 1 50 Vitamin E, vitamin C, (3-carotene and vitamin 
A all may act as antioxidants. 149 
Vitamin E (a-tocopherol), the major lipid-soluble antioxidant,149,151 protects against 
lipid peroxidation. Vitamin C quenches free radicals as well as singlet oxygen and 
can also regenerate the reduced antioxidant fonn of vitamin E69,149,151 (Figure 569). (3­
carotene is a quencher of singlet oxygen, and vitamin A scavengers the lipoperoxyl 
radical,152-154 and therefore, they both have antioxidant properties. 149 
Figure 5: Interaction between free radicals, and vitamins E and C. 

The free radical R . transfers its extra charge to vitamin E, thereby converting the 

vitamin to the tocopheroxyl radical. This then passes the charge to vitamin C, which 

itself becomes a free radical, while vitamin E is regenerated. The vitamin C then 

passes the charge to NADH thereby, terminating the free radical propagation. 

R' Vitamin E NADH:Vitamin C' 
Vitamin C R-H ~ ~Itamin E' 
The western world has been reported to have a relatively low intake of antioxidant 
149
vitamins or a borderline antioxidant vitamin status. Other nutrients such as 
flavenoids and other food components (in vegetables, fruits, seeds, nuts, tea and 
wine), as well as zinc and selenium, may also contribute to the antioxidant and free 
radical scavenging capacity of the diet. 149 
The antioxidants act synergistically, and metabolic interrelations exist between 
antioxidant nutrients with benefiGial protection and regeneration. 1 49 
Vitamin E and vitamin C synergistically inhibit the oxidation of liposomal 
membranes and LDL.69,149 Ascorbic acid scavenges aqueous radicals and also acts as 
a synergist to regenerate a_tocopherol.69,149,151 (3-carotene and vitamin E may also 
have an additive synergistic effect,149 as does retinol. In fact retinol may have greater 
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antioxidant potential when acting together with a-tocopherol, than when acting 
alone. 148 Furthermore, retinol may also regenerate a-tocopherol from the 
tocopheroxyl radical.154 
The location of the antioxidant in the membranes and lipoproteins and its mobility in 
this environment are also important. ~-carotene, which is less reactive than a-· 
tocopherol and ascorbic acid, is found in the inside of the lipophilic domain in the 
membrane, making it easier for it to scavenge lipophilic radicals. a-tocopherol, on 
the other hand, is found at or near to the membrane surface, and the efficiency of this 
antioxidant decreases as it gets deeper in to the membrane. 149 Ascorbic acid, which 
acts in the aqueous phase, and a-tocopherol, in the lipophilic compartment, interact 
at the interface between the membrane of lipoprotein and water. They inhibit 
oxidation synergistically, but a-tocopherol is more potent and more effective at 
scavenging radicals.149 
There is also a complementary effect of antioxidant nutrients in protecting different 
tissues or cellular compartments. Glutathione, ascorbic acid and a-tocopherol are all 
components of a regenerating redox cycle. a-tocopherol, is the major membrane­
associated antioxidant. It scavenges lipid peroxy free radicals and interrupts the chain 
reaction of lipid peroxidation, becoming oxidised in the process. Vitamin C (ascorbic 
acid) is a scavenger of neutrophil oxidants and converts the tocopheroxyl radical 
back to the active a-tocopherol. In this way the antioxidant activity of vitamin E is 
replenished,69,149,151 and further oxidation induced by this radical is prevented.69 
Glutathione, found in high concentrations in red blood cells, is capable of reducing 
oxidised vitamin C. Therefore these three antioxidants act together to protect tissues 
from oxidative damage. A change in anyone of these antioxidants may, therefore, be 
balanced by changes in the other two, and in this way a-tocopherol may be spared.149 
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Recent evidence suggests that there may a link between increased oxidative stress, 
and a decreased antioxidant status in chronic conditions such as pancreatitis,155,156 
HIV,157 coronary heart disease,158 cancers,158 and more recently IBD. 
2.3.2.1 Antioxidants and Pancreatitis 
Oxidative stress has been implicated in the pathogenesis of pancreatitis. Increased 
free radical activity is a common finding in pancreatitis. 155 Suboptimal availability of 
. antioxidants in the face of increased demand, especially for those substances that 
protect cells against non-biological free radicals - may be the most important 
factor. 156 In fact an antioxidant supplement, has been shown by Uden et aI, to 
significantly reduce the attack rate and background pain in chronic pancreatitis, as 
well as to nonnalise the suboptimal serum levels of selenium, ~-carotene and vitamin 
E in these patients.159 The reason for the low serum concentrations of these vitamins, 
and vitamin A remains controversial, 160 but may be due to inadequate intakes. 161 
2.3.2.2 Antioxidants and HIV 
HIV infection results in the progressive development of opportunistic infections and 
malignancy due to immunological changes, which eventually results in AIDS. 
Oxidative stress induced by the production of ROMs may add to the progression of 
the disease. In HIV patients without active opportunistic infections, there may be 
increased oxidative stress and weakened antioxidant defences with decreased serum 
levels of vitamin C, a-tocopherol, ~-carotene and selenium, and increased levels of 
lipid peroxides. 162 Furthennore, oxidative stress has also been implicated in HIV 
replication. 162,163 
2.3.2.3 Antioxidants and Coronary Heart Disease 
Recent evidence indicates that it is the oxidised products of fats, cholesterol and 
linoleic acid, and not the fats themselves, that are deposited in the arterial walls 
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fonning atherosclerotic lesions. The oxidisation may be consequent to cigarette 
smoking and industrial pollutants. l64 Antioxidants including vitamin A, ~-carotene, 
vitamin C and vitamin E, are thought to prevent atherosclerosis, by preventing the 
oxidation of low density lipoprotein.149,165 Vitamin C and retinol, however, may also 
exert a protective effect through the restoration of tocopherol to the reduced 
state. 154,1 66 
In the last two decades, studies have suggested an inverse relationship between the 
amount of fruit and vegetables that are eaten, and coronary heart disease. 149 More 
recently, studies have shown that there is a significantly decreased incidence of 
cardiovascular disease among those who have high plasma levels of ~-carotene,149 
vitamin E,149,167-169 and C. 166 This however, remains controversial. 149,169 
2.3.2.4 Antioxidants and Cancer 
Dietary intake of ascorbic acid, tocopherols, vitamin A and ~-carotene, has been 
linked to a decreased risk of various cancersI49,158,170-172 including colorectal 
cancer,149.170 breast cancer,149,171 pancreatic and gastric cancers,149,172,I73 lung cancer 
149,170 and bladder cancers. 149 However, in the ATBC lung cancer study, in which 
29133 male heavy smokers between the ages of 50-59 years were studied, it was 
found that the use of ~-carotene supplements of 20mglday was associated with a 
significant increase in the incidence oflung cancer. 149,174 Similarly, the Carotene and 
Retinol Efficacy Trial (CARET), which tested the chemopreventative effects of 
administering ~-carotene and vitamin A together, found lung cancer was 
significantly more frequent in the group which received relatively high doses of ~­
carotene (30mglday) and vitamin A (25 OOOIU retinol) for an average of 4 years, 
than in the placebo groUp.149,169 
The mechanism by which antioxidants are involved in carcinogenesis is not known. 
Free radicals may damage the DNA which can lead to cancers, however, they may 
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also act independently as tumour promoters. All antioxidants might also, to a certain 
extent, modulate secondary messengers, such as by the inhibition of adenylate 
157
cylase. Furthermore, antioxidants themselves may act as pro-oxidants under 
certain circumstances,174 and indeed, p-carotene in high doses under highly oxidative 
conditions, such as in smokers and alcohol users, results in oxidative breakdown 
products which may interfere with retinoic acid binding to retinoid receptors.175 
Furthermore, these breakdown products may induce local enzymes in the lung such 
as the P450 enzymes, which increase the catabolism of retinoic acid.176 This may 
explain the increased incidence of lung cancer in the above studies, but further 
research is needed in this regard. l77 
2.3.2 	 Antioxidants and Inflamnlatory Bowel Disease 
Due to the potential role of free radicals and reactive oxygen metabolites in the 
pathogenesis of IBD, recent research has examined the role that antioxidants play in. 
the disease. 
Various studies have shown· decreased serum antioxidant vitamin concentrations in 
IBD patients, however, results remain conflicting and controversial. Geerling et aI, 
found decreased serum concentrations of p-carotene, vitamin C, vitamin E, selenium 
and zinc in 32 CD patients compared to controls.74 Kuroki et ai, showed that 
although their CD patients were depleted in vitamin A and E, they were not deficient 
in vitamin C. The authors postulated that vitamin C remains unchanged until the 
disease has severely progressed.35 Another similar study ofboth UC and CD patients, 
reported that patients had lower serum levels ofvitamin A, p-carotene, vitamin C and 
vitamin E. However, serum lipid levels were noted to be low, and when vitamin E 
was expressed as a vitamin Enipid ratio, no difference to controls was evident.178 A 
further study of 137 CD patients, also reported low levels of serum p-carotene levels, 
but normal serum retinol values.33 Ascorbate levels were also reduced in these CD 
patients, and did not appear to be affected during therapy (prednisone or 
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sulfasalzine). A reduced dietary intake of vitamin C was considered the most likely 
explanation for the low levels.37 In a study by Hoffenberg et aI, in which 24 children 
with inflammatory bowel disease were studied, it was shown that the children with 
CD were particularly malnourished, compared to those with DC, and the control 
group. The children with CD had decreased ascorbic acid plasma levels, and 
increased glutathione peroxidase, glutathione, and a-tocopherol levels compared to 
the controls. The DC group had a trend toward lower ascorbic acid concentrations, 
and they also had decreased retinol concentrations compared to CD patients. The low 
serum vitamin C concentrations were thought to be consistent with colonic 
inflammatory disease. There were no significant differences in plasma selenium, p­
carotene, y-tocopherol or retinol binding protein (RBP) values between DC, CD and 
controls.38 
There are reduced concentrations of superoxide dismutase and metallothionein in the 
intestinal mucosa of those with IBD. These enzymes contain zinc and copper and are 
known antioxidants. Therefore, their reduction in IBD, may decrease intestinal 
protection against oxidant damage and treatments aimed at increasing the mucosal 
concentrations of copper/zinc containing antioxidant proteins may be useful in the 
treatment offfiD.64 
Although several studies have reported reduced antioxidant status in IBD, few have 
studied the role of supplementation in ffiD. Wright et al,179 was unable to 
demonstrate any effect on relapse rates in eighty six CD patients supplemented with 
50 OOOD vitamin A twice a day. 
The alterations in circulating concentrations of antioxidant vitamins and minerals, 
suggests an imbalance in antioxidant defences in ffiD, primarily in those with CD.38 
The precise role of this in the promUlgation of active disease is, as yet, unclear. 
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2.3.3 Vitamin C 
2.3.. 3.1 Chemistry 
Ascorbic acid (AA) is soluble in water, slightly soluble in alcohol, and insoluble in 
organic solvents. In aqueous solution, the compound is easily oxidised to the diketo 
form, dehydroascorbic acid (DHAA). The term vitamin C is used for all compounds 
that have qualitatively the same biological activity as ascorbic acid. Therefore, this 
term refers to either or both of the common biologically active forms, AA and 
DHAA.70 
2.3.3.2 Dietary Intake and Requirements 
More than 80% of the vitamin C in western diets comes from food or vegetable 
origin, mainly citrus fruits, green vegetables, peppers, tomatoes, berries and potatoes .. 
A small portion comes from fortified products, meat, fish, poultry, eggs and dairy 
products. Essentially none comes from grains.70 AA is easily destroyed by oxidation, 
especially in the presence of heat and alkalinity. It is also highly water soluble. 143, 
Therefore, the amount of available vitamin C in foods may be significantly reduced 
because of the destruction that occurs during cooking and loss in cooking 
water,70,180,181 as well as the addition of sodium bicarbonate to preserve the colour of 
cooked vegetables. 182 
The dietary requirement for vitamin C remains controversial and ranges from 30mg 
per day (United Kingdom and WHO) to 75mg per day (West Germany).70 However, 
an optimal vitamin C intake, of 200mglday has been proposed, in order to decrease 
risk of various diseases such as coronary heart disease. 180,183 The recommended 
dietary allowance (RDA) however, recommends a daily intake of 60mg per day, 184 
which provides plasma and leukocyte AA levels above the "at risk" or low levels of 
O.4mgldl. An intake of 60mg of AA per day is easily achievable in a normal western 
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diet.70 However, it has been proposed that an increased intake should be 
recommended for smokers,1°,185,186 the elderly, and for the ilL70 
2.3.3.3 Status Assessment 
There are a number of methods for assessing vitamin· C status, however, only the 
most practical methods will be discussed in this section. 
Measurements of plasma and leukocyte AA levels are currently the most practical 
and reliable tests of assessing human vitamin C status. Plasma levels are responsive 
to recent dietary intake, whereas leukocyte levels reflect tissue contents. Plasma AA 
tests are preferred for large population studies because the test requires less blood, is 
easier to perform, and the results are relatively easy to interpret.7o In healthy, fasting 
subjects the concentration of vitamin C in plasma can range from 25-80/-tmol!L (0.4 
- 1.4mgldl).180,187.188 Serum/plasma measurements will therefore be used in this 
study. 
Whole blood or erythrocyte AA levels are thought to be less sensitive indicators of 
AA deficiency, but are qualitatively the same as plasma.7o 
Urinary AA content is not useful for differentiating between subjects with normal or 
low AA status as the rate of excretion ofurinary AA is not linear with AA intake due 
to efficient renal reabsorption at low AA intakes, and renal clearance at high intakes. 
However, measurement of urinary AA levels after a loading dose of 0.5 to 2g of AA 
over 4 days can be useful for assessing a tissue ascorbate deficit. Excretion of less 
than 60% ofthe dose indicates depletion of tissue AA.70 
Women tend to have higher vitamin C concentrations than do men.70,I87,188 Smokers 
have been shown to have lower AA levels in plasma and leukocytes, and lower 
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dietary AA intake of smokers only partially explains the lower levels. Plasma levels 
of AA may also decrease with age. 187,189 
Interpretive Guidelines 
The generally accepted interpretation ofplasma levels is illustrated in table 4. 
Plasma umol/L (mg/dl) 
Normal Range 23 - 84 (0.4 1.5) 
Low 
-
11.4 - 23 ( 0.2 0.4) 
Deficient <11.4 «0.2) 
)lmol/L + 56.8 = mgldl 
Table 4: Plasma levels of vitamin C for status assessmeneo. 
2.3.3.5 Metabolism 
The intestinal absorption of faA and its entry into cells may be facilitated by 
conversion into DRAA, which penetrates membranes better than the reduced form at 
physiological pH, and is readily reduced back to AA in cells.70,190 Seventy to 90% of 
the usual dietary intake of AA is absorbed. Ingestion of several spaced doses of less 
than Igram throughout the day, are absorbed maximally, rather than the ingestion of 
a single megadose. This is probably due to a saturable absorption mechanism.7o 
Intracellularly, AA is almost entirely in the reduced form, and is localised to the 
cytosol which suggests a protective antioxidant function. In the plasma vitamin C 
exists in the free (nonprotein-bound) and reduced form.70,191 
The amount of AA excreted depends on the amount of AA cleared by glomerular 
filtration which depends on the plasma AA level and the glomerular filtration rate.70 
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As this amount increases, the ability of the renal tubules to resorb AA reaches a 
maximum, at the urinary re-absoprtion threshold of about 85J.1moVL, and the 
unresorbed excess AA is excreted in the urine,185,192 which is the main route of AA 
elimination.70 Negligible amounts of AA or its metabolites are excreted via faeces. 
The percentage of unmetabolised AA excreted in the urine relative to catabolic 
products increases with increasing dietary intake. A small amount of AA is converted 
to oxalic acid (5-10%), and is found even at very low dietary AA intakes. With 
increasing AA intakes, however, conversion to oxalate is limited. 70 
The average half-life of AA in the adult human is 16-20 days. The whole body 
turnover of vitamin C or catabolic rate depends on the AA body pool size. Intake of 
8-10 mg per day of the vitamin is sufficient to provide enough AA to satisfy critical 
function arid prevent deficiency. 70 
2.3.3.5 Functions 
AA has numerous functions including collagen formation, carnitine biosynthesis, 
cross linking reactions and formation of connective tissue,1°,193,194 neurotransmitter 
synthesis, and the formation of norepinephrine. 180,195 It also has a role in the drug 
metabolising system that operates in liver micro somes and reticuloendothelial 
tissues,1°,196 as well as increasing the intestinal absorption ofnon-haeme iron.70 The 
functions of AA which are directly related to this thesis, such as 
anticarcinogensis,170,1 82 immunocompetence7o and apoptosis,197­199 are discussed 
below. 
Anti-carcinogenesis 
Vitamin C may also have anti-cancer propertiesl70,182 at high concentrations182 by 
inhibiting nitrosamine formation, preventing activation of carcinogens, enhancing 
detoxification of carcinogens, improving the immune response, and inhibiting the 
promotion phase. I 70 
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Immunocompetence 
A variety of immune-related functions have been associated with AA status, 
including decreased resistance to a variety of infectious agents during AA deficiency, 
effects on neutrophil activity, and lymphocyte blastogensis. Certain immune system 
modulators are affected by ingestion of AA, including levels of cyclic nucleotides in 
Band T cells, IL-l and levels ofhistamine, prostaglandins, and prostacylin.70 
Apoptosis 
At high concentrations, vitaminC induces apoptotic cell death, possibly due to its 
pro-oxidant activity. At lower concentrations however, AA acts as an antioxidant, 
and therefore inhibits apoptosis.197-199 
2.3.3.6 Deficiency 
If dietary intake is inadequate, scurvy can result. Some historically reported 
symptoms of scurvy may be due to coexisting nutrient deficiencies such as of 
thiamin, "wet beriberi" (oedema), vitamin A (night blindness), vitamin D (rickets) 
and folic acid (megaloblastic anaemia).7o 
Clinical scurvy is rare, but usually occurs in those with exceptionally poor diets, such 
as alcoholics and drug abusers, or in those who have a near total lack of AA­
containing foods. A greater proportion of low blood AA levels is found in the 
institutionalised elderly population, or those who are homebound or sick. 
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2.3.4 Vitamin A 
2.3.4.1 Chemistry 
Chemically, vitamin A is a subgroup of retinoids. The term vitamin A is used as a 
generic term for retinoids which have the same biological activity as all-trans 
retinoL 182,200 Precursor forms of vitamin A are those carotenoids that have the same 
biological activity of vitamin A after intestinal conversion of retinol. The most 
predominant carotenoid is p-carotene.201 
Except for water, vitamin A and carotenoids are soluble in most organic solvents. 
Their increased sensitivity to light, oxygen, acid and high temperatures202 demands 
that vitamin A (retinol) be stored in frozen serum in the dark at -20° C in sealed 
vials.203 Carotenoids are less stable than retinofoo and therefore require storage at 
_40°C.203 
The primary unit of biological activity for vitamin A is I I-tg of all-trans retinol. 
Although retinyl esters are more common than retinol in food and are almost always 
present in synthetic preparations of vitamin A, the biological activity is still 
calculated as the amount of all-trans retinol present.2oo 
About 50 carotenoids show pro-vitamin A activity. The most active pro-vitamin, is 
all-trans p-carotene, which is often found in food. Most other pro-vitamins are 
carotenoids, e.g. 0.- and y-carotene which show biological activities of between 20­
60%.200 
In order to express both preformed vitamin A and p-carotene equivalents as a single 
value, retinol equivalents (RE) were created. Il-tg RE is the equivalent of Il-tg all­
trans retinol, 6l-tg of all-trans p-carotene, or 12l-tg of other pro-vitamin A carotenoids 
in food,200 
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2.3.4.2 Dietary considerations 
Food and other sources 
Good dietary sources of prefonned vitamin A (retinyl esters) are liver, other internal 
organs, whole eggs, dairy products and whole small fish. Good sources of pro­
vitamin A carotenoids include carrots, dark green leafy vegetables, tomatoes, yellow 
maize, papayas, ripe mangoes,200,204 spinach, oranges200 and plums.204 The richest 
sources of prefonned vitamin A are the liver oils of marine fish and of marine 
mammals, whereas those of carotenoids are red palm oil and carrot oi1.2OO 
Requirements and recommended intakes 
The RDA of vitamin A in j..tg RE is shown in table 5. Ij..tg RE ::::: 3.5nmol, and is 
assumed to be nutritionally equivalent to I1nmol (6j..tg) of ~-carotene and to 22nmol 
(12j..tg) ofother pro-vitamin A carotenoids.2°O 
RDA for Vitamin A 
Category Age (yrs) Vitamin A (j..tg RE) 
Males 10-12 
12-70+ 
1000 
1000 
Females 10-12 
12-70 
800 
800 
Pregnancy +0 
Lactation 0-0.5 
>0.5 
+500 
+400 
" 
Table 5: Recommended dietary allowances for vitamin A184 
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Nutrient Interrelations 
Protein 
Protein deficiency reduces the carotenoid cleavage and the synthesis of retinoid­
binding proteins and receptors.200 
Fat 
Ten to twenty grams of fat per day is needed for efficient intestinal absorption of 
vitamin A and carotenoids. Vitamin A and fat must be eaten together.200 
Iron 
Plasma haemoglobin levels or iron status, are depr ssed in vitamin A deficiency and 
enhanced by vitamin A supplements. Vitamin A may act on the metabolism and 
storage of iron, or more probably, on the differentiation ofred blood cells in the bone 
200marrow.
Zinc 
In zinc deficiency, vitamin A in the plasma decreases, but that in the liver increases. 
Embryogenesis is impaired by deficiencies ofboth vitamin A and zinc. Zinc seems to 
playa general role .in gene expression, due to its requirement for the binding of any 
nuclear transcription factor to deoxyribonucleic acid (DNA).200 
VitaminE 
Vitamin E protects vitamin A from oxidation in the gut and presumably in the 
storage globules of the liver and other organs as well. Vitamin E reduces the rate of 
hydrolysis ofretinyl este!s in the liver.2OO 
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Other Nutrients 
Vitamin A may also react in various ways with vitamin C. vitamin K, vitamin D, 
calcium, copper and iodine?OO 
2.3.4.3 Status Assessment 
Large variations, from 0.15-0.45J..1mollL, were found the plasma levels of retinol 
concentrations in a study by Dimitrov et al. 205 Plasma vitamin A concentrations 
lower than 0.35J..1mollL «10J..1g/dl) are indicative of vitamin A deficiency. Levels 
higher than 1.05umol/L (>30J..1g/dl) are associated with a satisfactory status?OO 
Values above 21.5J..1g/dl are desirable for fJ-carotene. 206 
Serum levels of fJ-carotene are generally 10-15% higher in women,207-209 while 
retinol levels have been found to be higher in men.207,208 
2.3.4.5 Metabolism 
Preformed vitamin A and carotenoids in foods are released in the stomach during 
proteolysis. They pass with lipids into the small intestine where they are emulsified 
by bile, to form micelles. Bile salts also stimulate pancreatic lipase, which in tum 
hydrolyses retinyl esters to retinol. Seventy to ninety percent of retinol in a bile-salt 
containing micelle is absorbed from the small intestine, while retinyl esters are 
poorlyabsorbed.201 fJ-carotene is converted in the cytoplasm ofthe intestinal mucosal 
cells to retinyl esters while most pro-vitamin A carotenoids can be converted in the 
cytosol of the mucosal, hepatic and other tissue cells to retinol or retinoic acid. The 
bioavalibility of carotenoids is not known, as there is great variability in its 
absorption and conversion to retinol. fJ-carotene yields two molecules of retinol, 
which are mostly reduced and esterified to retinyl esters?OO Conversion of fJ-carotene 
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to vitamin A is regulated so that excess vitamin A is not absorbed from carotenoid 
sources. 1 82 
After absoprtion into intestinal cells, newly fonned chylomicrons, containing retinyl 
esters, are secreted into the plasma and converted to chylomicron remnants, which 
increases the relative concentration of retinyl esters.200 The chylomicron remnants are 
then internalised in the liver. Retinyl esters are hydrolysed and combine with cellular 
RBP in the cytosol of the hepatocyte. Retinol may be stored as retinyl palmitate in 
the hepatocyte, or it may be esterified. and stored in stellate cells. Under nonnal 
physiological conditions, stellate cells contain 80-90% of the stored vitamin A, 
hepatocytes 10-20% and other liver cells only a few percent. The stored vitamin A 
can be readily and completely mobilised.2°o 
The release of retinol into the plasma from storage sites includes a number of 

proteins including apo-retinol binding protein (apo-RBP) which is fonned in the 

hepatocyte. All-trans retinol combines with apo-RBP to fonn holo-retinol binding 

. protein (Holo-RBP). This is then transported through the golgi apparatus, and is 

secreted in to the plasma where it combines with pre albumin.2°o From the plasma 

Holo-RBP interacts with cell-surface receptors for RBP on target tissue cells. Retinol 

is internalised, while apo-RBP is modified in confonnation and released. This 

modified apo-RBP no longer binds retinol and is finally catabolised, mainly by the 

kidney.20o 
Although vitamin A is mainly stored in the liver, all tissues contain some vitamin A, 
with the main stores in the fat depots, lungs and kidneys.182 
Between 5 to 20% of ingested vitamin A and a large percentage of carotenoids, are 
not absorbed from the intestinal tract and are excreted in the faeces. Ten to forty 
percent of absorbed vitamin A is oxidised or conjugated in the liver and then secreted 
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into the bile. Most of these biliary metabolites are excreted in the faeces, and some 
vitamin A is excreted in the urine. Of the dietary vitamin A taken in, on average 10% 
is not absorbed, 20% appears in the faeces through the bile, 17% is excreted in the 
urine, 3% is released as carbon dioxide, and 50% is stored, mainly in the liver.200 A 
reserve supply gradually accumulates, which reaches its peak in adult life. This 
storage capacity allows for a temporarily reduced daily intake of vitamin A.200 
Factors which affect absorption 
Fat 
A higher fat diet seems to increase absorption.2os 
Supplementation 
Long term-supplementation with ~-carotene may affect the serum concentrations of 
other carotenoids and retinol. The mechanism for this is not certain, but may be due 
to supplemental ~-carotene modifying non ~-carotene fractions by altering their 
absorption, distribution, storage, utilisation or clearance. Metabolic substitution by ~­
carotene for biological functions of other carotenoids, for example larger conversion 
of~-carotene to vitamin A, .with less conversion of other carotenoids, e.g. (l­
carotene, may also change plasma levels. Alternatively, ~-carotene might cause the 
release ofother carotenoids from specific tissues into serum.141 ,174 
Medications 
Antihypertensive medication, in the form of diuretics mainly, may increase levels of 
retinol, but decrease levels of ~-carotene, possibly due to an increase in RBP 
concentration as a result of interference with its catabolism in the kidney. These 
higher levels ofRBP, together with an adequate intake of retinol, will result in higher 
levels of retinol in serum.208 The lower levels of ~-carotene, however, could be 
result of the haemoconcentration.208 
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Cholinergic or adrenergic agents, beta-blockers, acetylcholinesterase inhibitors, 
alpha-methyldopa, clonidine, hydralazine, replacement hormones and calcium 
channel blockers may also result in increased retinol concentrations, I 37 
Certain drugs such as sulfonamides, aspirin and other vitamins, as well as nitrates,. 
potassium chloride or antacids may decrease bioavailability ofp-carotene. 137,20S 
Food and Gastrointestinal involvement 
Inactivation by the gastrointestinal mucosa or by constituents of food, such as 
sulfides and acids, may reduce absorption ofp-carotene,20s 
Alcohol 
Alcohol consumers may have lower p-carotene concentrati~ns,206 due to a reduced 
intake.209 Retinol concentrations ~ay however, increase. 141 The exact mechanism for 
this remains unclear. Alcohol may cause oxidative stress which leads to greater 
antioxidant use and increased conversion of carotenoids to retinol. 141 However, 
smokers tend to have a greater alcohol consumption than non-smokers,211 therefore, 
the association between alcohol consumption and serum carotene levels may actually 
be a result of the strong correlation between smoking and drinking.167,209,212 
Smoking 
Cigarette smoking may decrease serum p-carotene concentrations,141,167,205,212 
however retinol concentrations s~em to be unaffected.207,213,214 The smoking-induced 
oxidative stress may increase p-carotene utilisation.207,214,215 Furthermore smokers 
tend to have' a lower intake of fruits and vegetables, and hence the antioxidant 
vitamins.167.214.21S 
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Oral contraceptives 
The use of oral contraceptives seems to be associated with large decreases in 
~-carotene levels among 35-44 year old women.206 Increased oxidative stress due to 
oral contraceptive use, which increases serum cQncentrations of copper, may result in 
the decreased ~-carotene levels.206 
Idiopathic 
Certain individuals absorb ~-carotene poorly, for no apparent reason, and would 
require greater supplementation doses to maintain the same tissue levels as others. 205 
2.3.4.6 Functions 
Vitamin A is needed for the proper functioning of most organs of the body. Vitamin 
A is a component of the visual pigments, and therefore, is essential for the correct 
workings of the photoreceptors in the rods and cones of the retina.182 It ensures 
proper bone development and maintenance, and may also influence the synthesis and 
secretion of various cytokines and growth factors.2oo 
Carotenoids and retinol prevent the oxidation of low-density lipoproteins and 
therefore reduce the formation of atherosclerotic lesions.149.152-154 They may also 
protect against the development of cortical cataract, and reduce the oxidative stress 
induced by smoking.20o Vitamin A aids in the immune response200 and may decrease 
the risk of certain cancers. 149,216 Retinol, may also effect apoptosis.217,218 Since these 
_ functions may have an association with the topic of this thesis, they are discussed 
briefly below. 
Immune Response 
In vitamin A deficiency, both specific and non-specific protective mechanisms are 
impaired. These ·include the humoural response to various infections, cell-mediated 
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immunity, mucosal immunity, natural killer cell activity and phagocytosis. When 
vitamin A deficient subjects are supplemented with vitamin A immunity improves.2oo 
Vitamin A deficiency also results in the depression of phagocytosis, especially the 
"oxygen burst" after the ingestion of a foreign body and the secretion of IgA. 
Furthermore, the reduction in the production of goblet cell mucins, both in the 
intestinal mucosa and in the conjunctiva of the eye may also be depressed.2oo 
In vitamin A sufficient animals, carotenoids also enhance the immune response.2oo 
Malignancy . 
Vitamin A intake has been associated with the reduced risk of various cancers.149.216 
The mechanism of this anti-cancer action is not entirely clear. Retinoids may 
enhance differentiation and maturation ofstem cells.2oo 
Despite the reported anti carcinogenic effects, carotenoid therapy has resulted in an 
increase in the risk of lung cancer in smokers. 150 Excess intake of retinol or its 
related compounds have been reported to be carcinogenic, especially when taken 
together with aicohol. I41 
Apoptosis 
~etinol induces cell differentiation and apoptosis,217 possibly by enhancing caspase­
3 activity.218 
2.3.4.7 Vitamin A status· 
Vitamin A status can be classified in to five categories: 
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1. 	 deficient characterised by clinical signs. 
2. 	 marginal- there are no clinical signs of deficiency, but individuals may show some 
impaired clinical responses, such as an impaired immune response. 
3. 	 adequate. 
4. 	 excessive - individuals also do not show clinical signs ofhypervitaminosis, but these 
signs may be induced by larger vitamin A intakes, or by infection, such as viral 
hepatitis. 
5. 	 toxic -characterised by clinical signs.200 
Eye conditions 
Vitamin A deficiency IS a serious nutritional problem in preschool children in 
southern and southeastern Asia, in parts of Africa and South America. The major 
signs of nutritional deficiency in preschool children are a history of night blindness, 
low serum vitamin A, and a sequence of abnonnalities of increasing severity in the 
conjunctiva and cornea of the eye (xeropthalmia). Keratomalacia may also occur.200 
Skin changes 
Vitamin A is necessary for maintenance of the skin. Retinoids stimulate basal cell 
proliferation but inhibit the transcription of several epidennal keratins.20o Therefore, 
vitamin A deficiency causes changes in skin structure and metabolism such as 
follicular hyperkeratosis and phrynodenna.2oo 
Hair follicles are particularly sensitive to vitamin A, and become obstructed and 
enlarged during vitamin A deficiency.200 
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High risk clinical situations 
Any fat malabsorption syndrome, such as cholestasis, cystic fibrosis, sprue, chronic 
diarrhoea, pancreatic insufficiency, and biliary cirrhosis decreases the digestion and 
absorption of vitamin A and carotenoids and may eventually lead to a state of 
vitamin A deficiency or depletion.20o Similarly, those on TPN require regular 
monitoring as the plastic tubing may absorb the vitamin A in the infusion fluid.2oO 
The liver is of primary importance in the storage and utilisation of vitamin A 
Therefore, long-term alcohol intake, even in relatively small amounts, may decrease 
vitamin A storage. In alcoholics, the symptoms of vitamin A deficiency that occur 
e.g. decreased dark adaptation, can be improved by supplemental vitamin A,200 
Even though oestrogens and oestrogen containing contraceptives cause an increase in 
the steady-state concentrations of Holo-RBP in the plasma, the rate of mobilisation 
of vitamin A from liver reserves is only slightly affected. Therefore, in otherwise 
healthy women, contraceptive use does not significantly change their vitamin A 
requirement.200 
2.3.5 Vitamin E 
2.3.5.1 Chemistry 
There are eight naturally occurring vitamin E compounds with characteristic 
biological activity. Four vitamers are part of the tocopherol family, and four are 
tocotrienols.216,219 For the purposes of this thesis, only the tocopherols will be 
considered. 
[d]-a.-tocopherol, is the most active isomer, and is found naturally in food, in 
d · ~ d 216 Th . . E .. faddition, p-, 6-, and y-tocopherols are also foun m 100 . e vltamm actiVIty 0 
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a vitamin E isomer depends not only on the compound's structure, but also on its 
relative absorption, uptake by target tissues, and turnover rate. [d]-a.-tocopherol has 
the highest vitamin activity of all the tocopherols at 1.1IU/mg.216 
2.3.5.2 Nutritional requirements 
The tocopherol content of diets shows great variation depending on harvesting, 
processing, storage, and final food preparation.216 
The minimum daily requirement of vitamin E is not known however, but for adult 
men, the level is above 2mg per day for dietary a.-tocophero1.216 
The RDA for vitamin Eis shown in table 6. 
RDA for vitamin E 
Category Age (yrs) Vitamin E (mg) 
Infants 0-0.5 
0.5-1 
3 
4 
Children 1-3 
4-6 
7-10 
6 
7 
7 
Males 11-51+ 10 
Females 11-51+ 8 
Pregnant 10 
Lactation lSI 6 months 
2nd 6 months 
12 
11 
Table 6: Recommended dietary allowances for vitamin E184 
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2.3.5.3 Status Assessment 
Serum has generally been used to assess total tocopherol concentrations.216 
Because of the marked influence of plasma lipids on tocopherol concentrations, 
various tocopherol/lipid ratios have been used to determine tocopherol 
concentrations more accurately.216 Since tocopherol is transported by the low density 
B-lipoproteins which are rich in cholesterol, the tocopherol to cholesterol ratio is one 
of these methods of determining vitamin E status. Furthermore, in a study 
investigating the use of different lipids to express serum tocopherol levels, it was 
found that the tocopherol to cholesterol ratio gave the best results when comparing 
tocopherol with individual lipid ratios, with 86% sensitivity and 94% specificity, and 
was also the most convenient assessment method.22o But, expressing tocopherol to 
apoliproteins Al and B may be a more accurate. measure of tocopherol 
concentrations.221 However, since tocopherol to cholesterol ratios are the most 
convenient, and have high specificy and sensitivity, the tocopherol to cholesterol 
ratio will be used to assess vitamin E status in this study. 
Blood levels of vitamin E often do not correlate with reported dietary intake,21 1 but 
are affected by supplementation. This may be the result of inaccurate assessments of 
vitamin E content of foods due to variability following cooking, processing and 
storage. ) 67 
The lower limit of "normal" . concentrations of vitamin E in plasma is +/­
11.5Ilmol/L.150 Blood levels tend to increase appreciably within a few days with 
222doses of IOOmg or more, but this is accumulated in the tissues at a slower rate.
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2.3.5.4 Metabolism 
The amount of tocopherol absorbed will vary depending on the amount of total lipids 
absorbed. However, the efficiency of absorption decreases as large amounts of 
tocopherol are consumed. An average absorption rate seems to be between 
50_70%.216 
Once absorbed, vitamin E isomers are transported with fat mainly by the lymphatic 
systems to the venous system. Tocopherols are distributed in plasma in association 
with lipoproteins; mainly low-density lipoproteins222 but no specific carrier protein 
has been identified.216,222 Most tissues take up ex-tocopherol, including the liver, lung, 
heart, skeletal muscle and adipose tissue. Fat continuously takes up vitamin E and the 
vitamin is concentrated wherever there are large amounts of fatty acids. But, the 
tocopherol stored in the adipocytes is not readily available to other tissues. If the 
vitamin intake is high, the majority of the vitamin E is stored in the liver, however 
the total body pool also increases.216 
In healthy individuals the concentration of tocopherol present in the tissues is related 
to the amount of tocopherol consumed, and the lipid content of the organ. In blood, 
the amount of lipid present also has a major influence, if not a determining role, on 
the level ofcirculating plasma tocopherols. 
The liver secretes very low-density lipoprotein (VLDL), which is enriched in 
ex-tocopherol. It is thought that a hepatic transfer protein is needed for this process. It 
is found only in hepatocytes, and transfers ex-tocopherol between liposomes and 
microsomes. The ability to transfer tocopherol is needed for the incorporation of 
ex-tocopherol into VLDL.219 
Other tissues may also have binding proteins for tocopherol, which are necessary for 
regulation and delivery to specific intracellular sites. Metabolism of vitamin E 
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involves the hydrolysis and shortening of the molecule to ultimately form 
tocopheronolactone. The major route of excretion of tocopherol metabolites appears 
to be faecal elimination, possibly in association with bile secretion.216 
Factors affecting absorption 
Vitamin E is fairly stable to heat and acids and unstable to alkalis, ultraviolet light 
and oxygen. It is destroyed when in contact with rancid fats, lead, and iron. There is 
no loss by extraction in cooking; however, freezing and deep-fat frying destroys most 
of the tocopherol present. Esters of tocopherol, e.g. tocopherol acetate, are not 
appreciably destroyed. 182 
Vitamin E levels are not affected by cigarette smokingI67,208,210,214,215 or alcohol 
consumption. 167,208,210,21 I 
Medications 
Anti-hypertensive medication (usually diuretics) may increase a-tocopherollevels,208 
due to the diuretics causing haemoconcentration. Furthermore, cholinergic or 
adrenergic agents, beta-blockers, acetylcholinesterase inhibitors, alpha-methyldopa, 
clinidine, hydralazine, replacement hormones and/or calcium channel blockers may 
also result in increased serum concentrations. 136 
Nitrates, potassium chloride and antacids may decrease vitamin E.136 
Fat malabsorption 
216Fat malabsorption often results in decreased absorption oftocopherols.
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Interaction between vitamin E and vitamin C 
As previously discussed, vitamin E and vitamin C act synergistically as AA acts in 
the aqueous phase, while a-tocopherol acts in the lipophilic compartment, and the 
actions of the two vitamins meet between the membrane of lipoprotein and water. ISO 
Vitamin C also acts to regenerate vitamin E.69,151 
2.3.5.5 Functions 
Vitamin E has many important functions including its ability to acts as a membrane 
stabiliser and inhibitor of 5-lipoxygenase activity.223 It also prevents protein kinase C 
membrane translocation and activation, thereby playing a role in cell growth and 
differentiation,219,223 as well as modulating gene expression219,224 preserving 
erythrocytes and preventing haemolysis. 219 Furthermore, vitamin E acts as a sparing 
agent,182,216 inhibits cellular proliferation,219,226 has a role in arachidonic acid 
metabolism/19 the NF-KB pathway,219,224 and apoptosis.229 Since these functions may 
directly relate to the topic of this thesis, they are discussed below. 
Sparing agent 
Vitamin E may protect protein sulfhydryl groups and act as a "sparing agent" during 
oxidative stress?16 In the gut, vitamin E may enhance the activity of vitamin A by 
preventing its oxidation in the intestinal tract.182 
Nuclear Factor KB 
Vitamin E may exert an effect on the signal transduction pathway of NF-KB, which 
may depend on its antioxidant function. NF-KB may be activated by oxidative 
stressors219,224 such as hydrogen peroxide and lipid hydroperoxides, and therefore, 
antioxidants may inhibit NF-KB activation219 (Figure 1). In a study undertaken by 
Suzuki and Packer in 1993, vitamin E acetate almost completely blocked the 
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activation of NF-KB, while a-tocopherol did not. However, vitamin E acetate does 
become esterified to a-tocopherol.224 This may imply that the free radical process 
that activates NF-KB may occur proximal to the membrane, possibly in the 
mitochondria219 and therefore membrane oxidation may be an integral step in the 
signal-transduction pathway.224 Furthermore, since the vitamin E content of cells 
does not decrease in response to TNF-a treatment, it is thought that the cell 
possesses a vitamin E recycling mechanism.224 
Arachidonic metabolism 
Arachidonic acid is acted on by the enzymes cyclooxygenase and lipoxygenase, 
producing eicosonoids. The products of the cyclooxygenase dependent pathway 
include prostaglandins, thromboxanes, and predominantly prostacyclins. Vitamin E 
modifies the production of prostacyclin (PGh). a-tocopherol, as well as p-, y - and 
o-tocopherol potentiate the release of arachidonic acid and thereby stimulate PG 12 
synthesis. It has been shown that oxidative stress decreases the production of 
prostacyclin. This may be due to a decrease in the effective concentrations of vitamin 
E in cells?19 Furthermore, because NF-KB sequences have been found in the 
upstream, regulatory portion of the gene for cyclooxygenase, the cellular redox state 
may be an important modulator of arachidonic acid metabolism.219 
Vitamin E may alter prostaglandin synthesis, via the modulation ofphospholipase A2 
activity,219,225 which then inhibits prostaglandin E2 (PGE2) synthesis.219 
Inhibition of cellular proliferation 
All forms (0.-, y- and 0-) of tocopherol, except p-tocopherol seem to have 
antiproliferative properties,219,2j6 at relatively high concentrations (>20mglL). But, an 
ester of a-tocopherol, a-tocopherol succinate, is an effective antiproliferative agent 
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at much lower «lmgIL) concentrations.219 However, this remams highly 
controversial. 
The succinate ester, which is delivered more effectively in culture than 
a-tocopherol, is highly effective in tissue culture systems and is the most active type 
of vitamin E in these systems. In culture systems, a-tocopherol succinate may be 
taken up and the ester bond may then be hydrolysed, releasing a-tocopherol. Since 
this a-tocopherol is then transported intracellularly, it may be the a-tocopherol 
which is the effector molecule.219 However, a-tocopherol succinate itself may have 
antiproliferative properties which may involve the modulation of gene 
expression.219,223 
The exact mechanism of how a-tocopherol inhibits proliferation is not known. 
Vitamin E may directly inhibit the stimulation ofphospholipase A2 by protein kinase 
C,219.226,227 which would prevent the release of arachidonic acid. Also, functioning as 
an antioxidant, vitamin E could protect highly unsaturated n-3 and n-6 fatty acids, 
which have antiproliferative effects,228 thereby preventing proliferation?J9 
Apoptosis 
Vitamin E impairs apoptosis. The mechanism for this is unclear, but may be related 
to its interaction with cytochorome c or its interaction with free radicals produced by 
7-ketocholesterol, a potent inducer ofapoptosis?29 
2.3.5.6 Deficiency 
Human vitamin E deficiency can be defined as "a low plasma (or serum) tocopherol 
level (below at least O.5mg/dl), accompanied by a low ratio of tocopherol to lipid 
andlor haemolysis of erythrocytes incubated in 2% hydrogen peroxide".216 The 
occurrence of vitamin E deficiency due to dietary origin is rare in developed 
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countries. However premature infants, patients with gastrointestinal diseases leading 
to steatorrhoea and malabsorption, and individuals with abetalipoproteinaemia have 
been shown to be susceptible to this kind of deficiency.216,222 
Human vitamin E deficiency is associated with in vitro haemolysis as well as 
decreased erythrocyte survival in vivo from diminished antioxidant activity. 
Therefore, vitamin E deficiency may also have haematological significance in those 
with intestinal malabsorption.216 
Neurological disease 
Neurological disease may occur as a result of vitamin E deficiency, especially in"" 
children. However, the characteristic neurological symptoms improve with vitamin E 
treatment and may be preventable in those with abetalipoproteinaemia.216 
Destruction of cellular membranes 
Destruction of cellular membranes may occur in patients with vitamin E deficiency, 
and lipopigment (ceroid) may be deposited in human tissues such as small intestine 
due to modified PUFA metabolism.216 
2.3.6 Vitamins C, A and E as antioxidants 
Vitamin C is the first line of defence against free radicals in the aqueous phase of the 
cell membrane in blood69,7o In fact, it contributes up to 24% of the total antioxidant 
power of plasma.180,230 It is the only scavenging antioxidant which can prevent 
initiation oflipid peroxidation. 180,231 
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Vitamin E may be the major lipid-soluble, chain breaking antioxidant in human 
plasma,151 and it helps to protect fatty acids in plasma membranes from 
peroxidation,215,219,232 by preyenting propagation ofperoxidation of lipids.233 Vitamin 
E may be recycled or regenerated thereafter by vitamin CI50 thereby inhibiting it's 
depletion.38 a-tocopherol, is found at or near to the membrane surface, and the 
efficiency of this antioxidant decreases as it gets deeper in to the membrane. 150 AA 
and a-tocopherol interact at the interface between the membrane of lipoprotein and 
water. 
Although the importance of carotenoids as antioxidants remai s controversial,234 a 
number of studies have indicated that both p-carotene and retinol do have antioxidant 
properties,149,152-154,235,236 and in certain tissues retinol may in fact be the most potent 
antioxidant. 152 Studies investigating antioxidant vitamins have generally included 
both retinol and p-carotene, I 40,237-241 and we therefore felt that they should be 
included in this thesis. 
Beta-carotene is found in the inside of the lipophilic domain in the membrane, which 
makes it easier for it to scavenge lipophilic radicals. Chemically p-carotene is less 
reactive than a-tocopherol and AA,150,234 but it may exert a cooperative effect with 
a-tocopherol by residing and scavenging radicals at different positions in the 
lipophilic compartment. 149 
All-trans retinol also acts as a chain-breaking antioxidantI52,153,236 and intervenes 
during lipid peroxidation by scavenging the lipoperoxyl radical. 152,153,235 
Furthermore, it acts synergystically with a-tocopherol, and may interact with the 
tocopheroxyl radical, thereby regenerating a-tocopherol. l54 Retinol also seems to be 
a more effective antioxidant when it acts together with a-tocopherol than when it 
acts alone, 148 possibly due to the limitation of the auto-oxidation of retinol. 148 
80 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
The Antioxidant Status of Inflammatory Bowel Disease Patients Literature review 
2.4 Conclusion and motivation for this study 
Recent research indicates that free radical production plays an important role in the 
pathogenesis of chronic inflammatory conditions such as UC and CD,56,57,61 and 
therefore protective mechanisms against these agents may be important in the control 
of these diseases. Several studies have indicated low antioxidant vitamin status in 
patients with IBD, however reports are conflicting,29,30,34,74 and the cause, and 
subsequent effects ofthese abnormalities remains uncertain. 
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3. Aims and Objectives 
3.1 Aim 
The aim of this study was to investigate serum antioxidant vitamin status in patients 
with IBD. 
3.2 Objectives 
The objectives of this study included: 
1. 	 To assess the nutritional and antioxidant vitamin status of patients attending the 
IBD clinic at Groote Schuur Hospital. 
2. 	 To investigate the relationship between dietary intake, nutritional status and 
antioxidant vitamin serum concentrations. 
3. 	 To relate nutritional status and antioxidant vitamin levels with disease type, extent, 
activity, relapse rates, and medications. 
4. 	 To assess the effect ofantioxidant supplementation on serum concentrations, 
disease activity, and quality of life in CD. 
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4. Methodology 
4.1 Study Design 
One hundred consecutive patients attending the IBD Clinic at Groote Schuur 
Hospital were interviewed and studied. These patients were matched with 44 healthy 
controls recruited from the staff and students in the hospital. Twenty three patients 
with inactive CD, who had experienced a relapse in the previous year, were 
randomised to, receive antioxidant or placebo, administered as a buccal spray and 
were monitored for a period of 6 months. The criteria of an active episode in the 
previous year was used in order to attempt to identify a group of patients who were 
most likely to relapse during the study period. 
The study was divided into three parts: 
1. 	 Assessment ofnutritional status. 
2. 	 Assessment of antioxidant status. 
3. 	 Double blind, placebo controlled trial assessing the effect of an antioxidant vitamin 
supplement on disease relapse rates. 
Permission to perform the study was obtained by the Research and Ethics 
Committee, University of Cape Town and informed, written consent was obtained 
from all subjects. Good clinical practices (GCP) were maintained throughout the 
study. 
4.1.1 Inclusion Criteria 	 -. 
1. 	 Definite diagnosis of IBD based on histologic or radiologic findings. 
2. 	 Above the age of 18 years. 
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4.1.2 Exclusion Criteria 
1. 	 Pregnant females. 
2. Clinically relevant organ failure or other diseases. 
3. 	 Inability to participate because of comprehension reasons. 
4. 	 Use of antioxidant vitamin supplements within 2 weeks before the start of the 
trial. 
5. 	 Extensive resectional surgery (>lOOcm) with short bowel. 
/ 
Part 1: Assessment of nutritional status 
4.2.1 Methodology 
4.2.1.1 Baseline data 
Baseline data was gathered from all subjects. 
1. 	 Case notes were reviewed in order to gain a thorough medical history of each 
patient. 
2. 	 Dietary infonnation was obtained. 
3. 	 Smoking habits were detennined. 
4. 	 Anthropometric measurements were taken. 
5. 	 Disease activity was assessed. 
6. 	 A blood specimen (20mls) was taken from each patient. 
Controls 
Results were evaluated in comparison to a group of nonnal healthy volunteers who 
were matched for age and sex. The controls were recruited from the staff and 
students in the hospital, and were not on any fonn of vitamin supplementation or 
medications. 
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4.2.1.2 Review ofcase notes 
Each patient's folder was reviewed in order to obtain the following infonnation: 
Biographical data 
1. Name. 
2. Gender. 
3. Date of birth. 
Medical history 
1. Type ofIBD. 
2. Date of diagnosis. 
3. The extent of disease. 
4. The number and duration of clinical relapses in the last year. 
5. The number of operations and extent and site of surgery. 
6. The type and dosage ofpresent medication. 
7. Any fonn of vitamin or nutrient supplementation being taken. 
Disease activity 
The CDAI was used to assess disease activity in CD, while the RBI was used in UC 
patients. Patients with a CDAI value of greater than 200, or a RBI value of greater 
than 10 were considered to have active disease (Appendix 4 and 5). 
4.2.1.3 Anthropometric data 
Anthropometric measurements were taken by the principal investigator throughout 
the study.· 
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Each subject was weighed in light street clothing using a Healthometer beam balance 
scale to the nearest 100g, and height was measured in stocking feet using a 
Healthometer measuring stick. The scale was checked for accuracy using a weight, 
and was corrected accordingly. Three measurements were taken and an average 
measurement was used. Body mass index (BMI = weightlheight2) was then 
calculated from this data. When analysing this data, BMI was used to group patients 
into weight categories. A BMI of less than or equal to 16kglm2, was considered to be 
severely malnourished. A BMI of between 16kglm2 and 19k9lm2 was considered to 
be moderately malnourished. A BMI of between 19k9lm2 and 25kglm2 was in the 
normal range. A BMI between 25 and 30 kglm2 was considered overweight, while a 
BMI ofgreater than 30kglm2 was termed obese. 
The patient's TSFs were measured to the nearest 1.0mm, using a set of Harpendon 
skinfold calipers placed midway between the olecranon and acromium of the right 
arm, with the arm relaxed and bent at the patient's side. MACs were also measured at 
the same point, with a tape measure to the nearest Imm, as a measure of muscle 
mass. Three measurements were taken, and average measurement was used. For 
analysis these measurements were divided into percentiles using national center for 
health statistics (NCHS) tables.9 
4.2.1.5 Dietary Information 
A semi-quantitative food frequency questionnaire, originally designed by Gladys 
Block and colleagues,133 was used in order to assess usual daily intake. The 
. . d b d· . . d . . t . d' 135·138 b t questIonnaIre use was ase on questIonnaIres use In preVIOUS s u les, u 
was changed slightly to include. South African terminology and available and 
commonly eaten foods, as found in a previous study9 (Appendix 3). The subjects 
were asked specific questions about the foods that were eaten, and were asked how 
many times a, week or month they were eaten. 
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Portion sizes were calculated using household food measures. Each subject was 
asked how much of each food was eaten at a time, and they were then shown various 
household utensils of different sizes. Furthermore, patients were also asked about the 
preparation method of the food, and whether the entire portion had been eaten. These 
were then recorded. In order to evaluate the portion sizes for analysis, the actual 
foods were weighed using the utensils, and a Soehnley kitchen scale. In order to 
analyse the intake on the Food Finder program, the analysis was reduced to a daily 
intake. 
Part 2: Antioxidant Vitamin Status 
4.3.1 Blood analysis 
Twenty millilitres of blood was collected for antioxidant vitamin analysis. These 
tubes were covered in foil, to protect them from light, and were centrifuged within 10 
minutes of being drawn. Serum was extracted, stored in foil covered test tubes, and 
coded. All vitamin determinations were subsequently performed, using recognised, 
validated techniques, by the principal investigator in a blinded fashion. Training and 
supervision was provided by Dr. J Ogden, a PhD research scientist in the 
Gastroenterology Clinic, and Mrs. M. Callanan (National Diploma Medical 
Technology), a medical technologist with 4 years of experience working on HPLC. 
4.3.1.1 Vitamin C analysis 
Serum for vitamin C analysis was kept at 4° C until it was analysed. All the blood 
was analysed within 3 hours. after being drawn. The vitamin C assay was performed 
colourometrically, according to the method described by Tietz et at242 (Appendix 7). 
Standards for the vitamin C analysis were freshly made up according to the 
method,242 for each day of analysis. Quality assurance data are shown in table 7. We 
were unable to calculate the between batch coefficient of variation for vitamin C 
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analysis, as fresh blood was required for the analysis method,242 and therefore the 
same blood could not be compared between batches. 
Coeffecient ofvariatiation (%) 
Measurement Material Method Within Batch 
AA Serum Colourometric""'" 1.34 
Table 7: Quality Assurance Data for AA Analysis 
4.3.1.2 Analysis for vitamin A and E 
Blood serum vitamin levels for vitamins A, E and p-carotene were analysed using 
HPLC243 (Appendix 8), and were kept in foil covered containers, in the dark at -650 C 
until analysed. Furthermore, the samples were also analysed in the dark in order to 
minimise vitamin loss during analysis. The standards for the HPLC analysis were 
made up according to the method used243 and were also stored in foil covered 
containers, in the dark at -65°C until used. Each standard was defrosted a maximum 
of 4 times before being discarded and were run at the beginning of a days' analysis. 
Quality assurance data are shown in table 8, and the precision of the analysis has 
been reported to be "acceptable for this type of analysis".243 
Coeffecient ofvariatiation (%) 
• Measurement 
I 
Material Method Within Batch Between Batch 
I Retinol Serum HPLC"...> 5.17 (3.8)# 10.03 (8.2t 
• p-carotene Serum HPLC"''''' 8.46 (7.0)" 14.73 (13.9)" 
a-tocopherol Serum HPLC'"'' 5.48 (4.9)" 14.63 (13.2)" 
# - coeffeclent ofvanatlOn (COV) as a percentage are shown: COY from our data (COV 
from metbod243) 
Table 8: Quality Assurance Data for Retinol, l3-carotene, and a.-tocopherol Analysis 
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Part 3: Antioxidant supplementation trial 
4.4.1 Study population 
Previous studies have indicated that approximately 70% of patients with CD, who 
have had a previous active episode within the previous year, would experience a 
relapse within 6 months. I II In the same study, use of AZA as a maintenance agent 
reduced the relapse rate to 35%. With these figures in mind, and an a value of 0.05, 
at a power of 90%, a sample size of 20 was calculated to be sufficient to demonstrate 
a significant difference. Therefore, 23 patients with CD who had experienced a 
relapse within the previous year were randomised into a supplementation trial. 
Vitamin supplementation was provided by Vitamist antioxIdant vitamin sprays®. 
The contents ofthe spray is shown in table 9. 
Vitamin Amount %RDA 
VitA 1000 RE 100%RDA 
J3-Carotene 25ri1g 10%RDA 
Niacin !3mg 20%RDA 
VitC 6mg 10%RDA 
VitE 10mg a-tocopherol 
equivalents 
100%RDA 
Table 9: Contents of the antioxidant spray 
These vitamin sprays are sprayed into the mouth, and may be absorbed through the 
buccal membrane,244-247 or through the stomach when swallowed. Buccal spray 
formulations have been reported to have an absorption rate of 96%,248 which is 
greater than oral fomulations.248 Furthermore, ease of application, and patient interest 
in this form of delivery mechanism, as well as claims of the manufacturers regarding 
the efficacy of the product in the management of chronic inflammatory conditions 
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persuaded us to submit the product to clinical trial. The antioxidant sprays and 
placebo sprays were provided by the company (Karemore: Vitamist) in identical 
containers, and were coded for subsequent analysis following the study. 
Although the dosages used were modest in comparison to some supplementation 
trials,178.249,250 the dosages used for vitamins A and E were 100% of the RDA, and 
the ~-carotene dosage was equivalent to other supplementation trials. 140,249.251,252 We 
had noted that the subjects were taking in adequate amounts of vitamins in their diets 
(greater than 100% RDA). Since, over supplementation of certain vitamins, such as 
carotenoids may be associated with adverse effects including an increased risk of 
certain cancers,173.253 we elected to use the dosages recommended by the 
manufacturer of the formulation for the management of chronic inflammatory 
disease. In view of the formulation of the product, the study was concerned with the 
effect of supplementation of vitamins A and E. The role of supplementing vitamin C 
was not fully assessed in this study. 
In order to assess vitamin status, results were evaluated in comparison to 23 of the 
controls who were matched directly to patients on the supplementation trial for age, 
sex and BMI, and were also studied further. 
4.4.1.1 Inclusion Criteria 
1. Patients who had previously qualified for the antioxidant trial. 
2. Known CD as identified by pathological and/or radiological findings. 
3. A history of at least one active episode in the previous year. 
4. Clinically inactive disease reflected by a CDAI score of less than 150, at the time 
of entry into the study. 
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4.4.1.2 Exclusion Criteria 
1. A CD AI score of greater than 150. 
2. Those on immunosuppressive therapy. 
3. Those on corticosteroid therapy. 
4. Those with abscesses or fistulae. 
4.4.2 Methods 
1. Patients were randomised to receive either active supplement or placebo for a 
period of 6 months. 
2. The sprays were administered by using 2 sprays, 4 times per day which delivered 
100% of the RDA for both vitamin A and E, and 10% of the RDA for vitamin C 
and p-carotene in the active group. 
3. Patients were instructed to be nil per mouth from 100' clock the previous night for 
each visit. 
4. Patients were assessed monthly for a period of 6 months. 
At the 1 sl visit or baseline visit for the supplementation trial 
1. 	Blood was taken, for vitamin analysis, cholesterol levels, full blood count and 
ESR. 
2. 	 Each patient completed a semi-quantitative food frequency questionnaire. 
3. 	Instructions on the use of the supplement were given. 
4. 	Patients were encouraged not to change their eating habits during the course of the 
trial. 
5. 	Patients were also encouraged not to take any other antioxidant vitamin 
supplements during the trial. 
6. A clinical disease activity index (CDAI) was completed for each patient. Another 
form was given to each patient to take home, to be filled out every day for a week 
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before the following visit to ensure accuracy of the data. Instructions were given 
about how to fill in the form. 
7. A quality of life questionnaire using the SF-36 QOL survey was also completed. 
8. Weight and height were measured, and recorded as above, and BMI was 
calculated. 
Subsequent visits 
1. Compliance was checked and noted. 
2. Any adverse events, or change in medications were noted. Any adverse event that 
. was 	reported was then also assessed by a doctor who determined severity of 
symptoms. The patient then continued on the trial or was withdrawn. 
3. The semi-quantitative food frequency questionnaire was completed at each visit in 
order to ensure that patients had not altered their diets in any significant way from 
month to month. 
4. A fasting blood specimen was taken. 
5. Disease activity was assessed, and a new form was supplied for the next visit. 
6. QOL questionnaire was completed. 
7. Weight was measured and recorded, and BMI was calculated. 
4.4.2. 1 Withdrawal Criteria 
Patients were withdrawn from the trial on the following criteria: 
1. A CDAI score greater than 200. 
2. The development of disease complications. 
3. Users of outlawed medications or vitamin supplements. 
4. Patients who were lost to follow up. 
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4.4.3 Blood analysis 
The blood analysis for this part of the trial was the same as above. Analysis of 
retinol, p-carotene and a-tocopherol was by HPLC,243 and that of vitamin C was by 
colourometric method.242 Furthermore, a sample of blood was also sent to the 
Chemical Pathology Laboratory at Groote Schuur hospital for cholesterol analysis, 
which was then used to determine the a-tocopherol to cholesterol ratio, in order to 
determine the vitamin E status of the patients, more accurately. 
4.4.4 Data Analysis 
All data from the questionnaires and from blood results was coded and captured into 
Microsoft Excel 7.0 computer programme. 
The semi-quantitative -food frequency questionnaires were reduced to one day's 
intake, and were analysed using the Food Finder programme (version 4) which 
correlated the data into macro and micronutrients. American recommended dietary 
allowances (RDA) as well as the amounts of micro nutrients in milligrams were 
calculated. 
QOL analysis was based on the SF-36 QOL questionnaire (Appendix 9), and 
permission was granted to use this QOL form by Prof. John E. Ware. Because the 
QOL has not been fully validated in South African patients, the QOL assessment was 
based on analysis of change from baseline (Statistics department, U.C.T). Patients 
who defaulted from the intervention trial, were considered to be treatment failures in 
the analysis ofdata. 
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Data was analysed using the Statistica for Windows computer package. Pearsson's 
correlations, students T-tests (for parametric data), Mann-Whitney U-test (for non­
parametric data), Chi-squared tests, and ANOV A were performed as was applicable. 
Results were considered to be significant when the p value was found to be less than 
0.05. 
All results will be shown as means ± standard deviations (SD) for parametric data, 
and median (Lower Quartile-Upper Quartile) for non-parametric data. 
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5. Results 
5.1 Subject data 
One hundred consecutive patients (65 females and 35 males) were studied. The mean 
age of the group was 42.52±13.08 years. The patients were matched to a group of 44 
controls (Table 10). 
CD (n=56) . UC (n=44) Controls (n=44) 
age (yrs) 43.74±11.62 41.55±14.00 40.10±12.10 
male/female 19/37 16128 18/26 
Table 10: Subject data 
5.2 Anthropometry 
The mean weight of the patients was 65.50±15.25 kg, with a mean BMI of 
24.94±5.47 kglm2 (normal range 19-25 kg/m2). Mean TSF was 2.63±0.61 cm (50th_ 
75th percentile 2.5-3 cm), and the MAC was 27.79±5.29 cm (50th_75th percentile 
25.8-28.3 cm) (Table 11). 
There were no significant differences in mean anthropometric measurements 
between controls and subjects, and between CD and Uc. 
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CD (n=56) UC (n=44) Controls (n=44) 
BMI (kglmk) 24.53±5.64 25.46±5.28 L"'I 1l'\±3.22 
TSF (cm) 2.68± 0.73 2.59±0.52 2.43±0.61 
TSF (percentile) 50-85 50-85 50-85 
MAC (cm) 27.79±4.72 26.65±2.71 26.87±3.50 
MAC (percentile) 50-75 50-75 50-75 
Table 11: Anthropometry 
5.2.1 BMI 
Forty six percent of the patients interviewed had BMI values greater than 25 (Figure 
6). Thirty four percent of patients were overweight (30.35% CD; 38.64% UC), and 
12% were obese (12.5% CD; 11.36% UC). Forty one percent of the patients were of 
nonnal weight (41.07% CD; 28.64% UC), and 13% were underweight with 10% 
being moderately malnourished (12.51% CD; 6.81% UC), and 3% severely 
malnourished (1.79% CD; 4.54% UC). None of the controls were underweight, 
52.27% were ofnonnal weight and 47.72% had BMI values ofgreater then 25 (38.63 
% overweight; 9.09% obese) (Figure 6). 
BMI was found to be correlated with age for both CD (r=0.32; p=0.02) and UC (r= 
0.37; p=0.02). 
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Figure 6: Nutritional status distribution. 

8MI of greater than 30 is obese, 25-30 is overweight, 19-24.9 is normal, 16.0-18.9 is 

undernutrition (moderately malnourished) and a 8MI below 16 is severe malnutrition.13 
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Mean albumin concentrations were within the nonnal ranges for all groups and were 
similar between all the groups (Table 12). 
Total CD (n=56) UC (n=44) Normal 
Albumin 44.01±5.08 43.02±5.71 45.63±3.35 35-50g/1 
Table 12: Albumin concentrations 
Only 3 patients were found to have subnonnal albumin concentrations. All these 
patients had CD, were smokers and had ESR values above 20, indicating active 
inflammation. 
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5.2.2 Nutrient Intakes 
CD (n=56) UC (n=44) Controls (n=44) 
Energy (kcaV day) 2407±850.6 2790±375.4 1565±747.l 
% protein 10.89±2.27* 11.28±2.28* 13.45±2.59 
% fat 37.20±8.03* 35.02±7.02* 33.65±3.91 
% carbohydrate 50.l2±9.12* 52.38± 7.43 * 46.37±5.43 
% alcohol 0.234±0.64* 0.255±0.78* 6.91±4.91 
* p<O.O 1 vs controls 
Table 13: Intakes of macronutrients 
Although the total energy intake of subjects was higher than controls, the difference 
did not reach significance (p=0.12). Protein intake was significantly lower (p=0.001) 
(Table 13) and carbohydrate intake was significantly higher (p=0.016) than controls 
(Table 13). Furthermore, alcohol intake was significantly higher in controls (p<0.01) 
(Table 13). 
Nutrient intake did not correlate with BMI. 
5.3 Smoking 
Forty percent of patients with IBD compared to 20.5% of the controls smoked 
(p<0.01) (Table 14; Figure 7). 
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CD (n=55) UC (n=44) Controls (n=44) 
non-smokers n (%) 24 (43.63) 35 (79.54) 35 (79.54) 
smokers n (%) 31 (56.36) 9 (21.43) 9 (20.45) 
Table 14: Distribution of smokers 
Significantly greater numbers of smokers were found In CD compared to UC 
(X2=10.6; p<O.Ol) and controls (X2=11.64; p<O.Ol). The number of smokers in UC 
and controls were similar (Figure 7). 
Figure 7: Smoking prevalence. 
Percentage of patients in each group is shown 
*# 	 * p<O.Ol vs. controls 
# p<O.Ol vs. UC 
OOCO 
~UC 
• Controls 
There were no associations between the number of cigarettes smoked and BMI 
(r=0.074; p=0.64). 
5.4 Drugs 
At the time of interview the medications that patients were taking included steroids, 
salazopyrin and 5-ASA compounds, and immunosuppresives (Table 15). 
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CD (n=56) UC (n=44) 
Steroids n (%) 8 (15.38%) 6 (13.95%) 
SZP/ASA n (%) 14 (25%) 34 (79.07%) 
AZA/6-MP n (%) 6 (10.71%) 3 (6.98%) 
Table 15: Number of patients on each 1f.,"'.. ..-"1 at time of interview 
Other medications included iron 16.28%), 
antidiarrhoeals eg imrnodium and CO(leUle ""''"V'''IJU''''''.. 11.63%) and 
in smaller amounts paracetomol, flagyl, of 
interview, no patients were taking any antioxidant vitamin 
There were no significant differences hetwec:m status of those patients 
on medication and those patients not on l,,",YJ',,","'LIVH both between the 2 
groups. 
5.5 Duration of disease 
The median duration of ........,,",...."'''' was 7.32 (Quartile range 

5.0-15.0 yrs) (Table 16). 
Table 16: Median duration of (Quartile Range) 
was similar (Table 16). was no 
'.H':>'_o..:>v and BMI (CD r=0.065; p=0.66, 
p=0.24). 
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5.6 Site of disease 

In patients CD, 'AI"""",,, location was assessed as ileal, colonic, and ileocolonic. 
UC were divided into total colitis, left sided and proctitis 17). 
CD Site Number(%) UC Site Number (O/o) 
. Ileal 17 (30.35%) Total Colitis 19 (45.23%) 
Colitis 25 (44.64%) I Left sided (h~ea~e 10 (23.81%) 
Ileocolitis 14 (25%) Proctitis 13 (30.95%) 
Table 17: Location of disease for CD and UC 
I 
There was no significant association between and extent of ....,,',"'''''' and 
nutritional status. 
5.7 Disease activity 
mean of the IBD patients was 24.99±22.41 mmlhr. This was similar 
the two groups, as shown in table 18. mean CDAI of the patients 
was 103.25±75.24, and the mean RBI for the UC patients was 7.25±1 (Table 
18). 
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Disease Activity 
marker 
CD UC Normal Range 
ESR(mmIhr) 26.84 ±23.38 21.85±20.73 0-10 
CDAI 103.2S±75.24 0-150 
Harvey Bradshaw 7.25±13.39 0-10 
Table 18: Disease activity markers 
5.7.1 Disease activity in CD 
Forty two patients CD were in remission (CDAI<150) at the time interview, 
and 3 had evidence of active disease (CDAI >200) (Table 19). 
Table 19: Disease activity as measured by the COAl 
Neither the CDAI or the were to (eDAI 
16, ESR r=-0.0002; p=0.99). 
5.7.2 Disease activity in DC 
Using the HBI, of the patients (75.00%) were remission at of 
interview. HBI was not significantly correlated with BMI 17; p=0.54). 
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5.8 Disease Relapse Rates 
Seventy-six ....prl~pnT of one or more relapses in the 
previOUS year (Table 20). 
""......... ,'" had 
I No of people with relapses % of group 
CD 47 83.9 
UC 29 65.9 
Table 20: Relapse rates 
was no association .,,,,,,.,,.,"".,... relapse rates BMI (CD r=0.089; 
. p=0.68), the number of cigarettes smoked 
,,-\l.J..... 
p=0.83, UC r=0.096; 
p=0.54), 1, UC duration of (CD r=­
UC r=O.II; p=0.48). kn1"1rh"'rrn categories were 
more prone to relapse than others. In however, relapse rates were significantly 
the0.1 
positively correlated with 
were negatively with carbohydrate as a percentage of ","",rnu 
intake as a ,"porropnr" of (r=0.49; and 
8 and 9). p=0.006) 
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Figure B: Correlation between rp-/'!lD~:P- rates per year and fat intake as a percentage of energy in 
CD 
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5.9 Surgery 

Eight (14.29%) CD patients had undergone to the bowel, 3 (5.36%) 
patients undergone to the bowel, and a further 8 (14.29%) patients 
both their small bowel and large bowel operated on. Furthermore, 3 (5.36%) 
patients had experienced complications which had required surgical intervention. In 
all these patients, was but a 50cm of bowel 
had been removed, and none of the patients had clinical evidence of short bowel 
syndrome. 
UC, only 1 (2.27%) patient interviewed had ,n",,,,......,,,,...,o a colectomy. 
There was no ",v""'''''.,vu with BMI and "''''''1'11'<> procedures. 
5.10 Vitamin Status 
5.10.1 Vitamin C 
5.10.1.1 Intake 
mean C are In 10. All groups had mean intakes 
than 1 of the with intake in 168.9±1 RDA, 
189.1±132.3% RDA, and controls 173.9±94.3% RDA 10). There were no 
IHl\.,a.IU differences between the mean intakes of the 3 1".LVUIJ" 
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Figure 10: Vitamin C intake (% RDA). 
Means of intake are shown with errror bars representing SDs 
350 

300 

250
Vito C 
intake 200 (% RDA) 
150 

100 

50 

0 

fmI CD 
~UC 
• Controls 
Total CD UC Controls RDA11S4 
Vit C (mg) 120.6±76.23 123.6±167.9 116.4±77.5 116.2±63.0 60.0 
VitC 
(%RDA) 
163 .5± 126.2 168.9±133.7 189.1±132.3 173.9±94.3 100.0 
Significantly more patients took in less than 100% of the RDA for vitamin C 
compared to controls (CD X2=11.09; p==O.OI, UC X2=7.2; p==O.OI) . The percentage of 
patients taking in less than 100% RDA were similar in the DC and CD groups (Table 
21). 
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Total CD UC Controls 
>100% RDA (%) 65 35 (62.5) 30 (68.2) 41 (93.2) 
100%<RDA<67% (%) 13 7 (12.5) 6 (13.63) 2 (4.55) 
67%<RDA<50% (%) 15 10(17.86) 5 (11.36) 1 (2.27) 
<50% RDA(%) 7 4 (7.14) 3 (6.82) 0 
Table 21: Number of subjects according to %RDA for Vit C (RDA=60mg 184) 
5.10.1.2 Serum concentrations 
Both CD and UC patients had significantly lower mean serum vitamin C 
concentrations compared to controls (UC 0.75±0.54 mgldl vs. 1.37±0.54 mgldl; 
p<O.OI, CD 0.93±0.48 mgldl vs. 1.37±0.54 mgldl; p<O.OI). There was no significant 
difference between CD and UC (Figure 11). 
Figure 11: Serum concentrations of Vitamin C (mg/dJ). 
Means of serum concentrations are shown with errror bars representing SDs 
2 
* p<O.OI vs. controls 
1.5 
Ii!ICDVito C 
~UCcone 
• Controls(mg/dl) 
0.5 
0 
Total CD UC Controls 
Vit C conc (mg/dl) 0.81±0.53 0.93±0.48 0.75±0.54 1.37±0.54 
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The Antioxidant Status of Inflammatory Bowel Disease Patients Results 
There was no correlation between intake and serum concentrations (r=-O.OS; p=0.52) 
and there was no significant difference in serum concentrations of those patients 
whose vitamin C intake was less than 100% RDA, and those in whom intake was 
higher (0.S1±0.59 vs. 0.79±0.43; p=0.90). Although there was a trend to decreased 
vitamin C levels with decreasing intake, the differences did not achieve significance 
(Figure 12). 
Figure 12: Serum vitamin C serum concentrations for the different vitamin C intakes according to 

. the ROA. 184 

Means of serum concentration (mg/dl) are shown with errror bars representing SOs. If there was 

only one person in a group, SOs are not shown 

* p<0.01 vs. controls 
III CD 
mlUC 
• Controls 
5.10.2 Vitamin A 
5.10.2.1 Intake 
There were no significant differences between mean vitamin A intakes of the various 
groups (Figure 13). The mean intakes of all groups was greater than 100% of the 
RDA with the intake of CD 154.9±S9.S6% RDA, UC 137.l±69.09% RDA and 
controls 10S.S±49.21% RDA. 
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Figure 13: Vitamin A intake (% RDA). 

Means of intake are shown with errror bars representing 5Ds 

250 
Vit.A 
intake 
(% RDA) 
200 
150 
100 
50 
0 
II CD 
~UC 
• Controls 
Total CD UC Controls RDA1 !S4 
Vit A (RE) 1255±763.0 1305±818.5 1194±693.1 902.1±444.1 1000 
Vit A (%RDA) 146.9±81.3 154.9±89.9 137.1±69.0 108.8±49.2 100.0 
Significantly more CD patients had intakes below the RDA for vitamin A compared 
to controls (X2=3.95; p=O.046) (Table 22). The number of UC patients who 
consumed less than the RDA was similar to controls (X2=2.25; p=O.13) and to CD 
(X2=O.04; p=O.84) (Table 22). 
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Total CD UC Controls 
>100% RDA (%) 66 36 (64.28) 30 (68.18) 37 (84.09) 
1 00%<RDA<67 % (0 17 (30.36) 10 (22.73) 3 (6.82) 
67%<RDA<50% (%) 3 2 (3.57) 1 (2.27) 2 (4.55) 
<50%RDA(%) 4 1 (1.79) 3 (6.82) 2 (4.55) 
Table 22: Number of subjects according to %RDA for vit A intake 
5.10.2.2 Serum concentrations retinol 

mean serum CD patients and the was 
controls (CD 0.41 mg/dl vs. 0.81±0.32 mg/dl; p<O.Ol, 
betweenmg/dl vs. 0.81±0.32 mg/dl; p<O.Ol). There was no 
serum of CD and DC (Figure 14). 
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Figure 14: Serum concentrations of retinol (mg/dl). 

Means of serum concentration are shown with errror bars representing SDs 

1.2 
* * 
* p<O.OI vs. controls 
1 
0.8 
00 CDRetinol 
0.6conc. mlUC 
(mg/dl) 
• Controls0.4 
0.2 
0 
Total CD UC Controls 
Vit A (mg/dl) O.4I±0.22 0.41± 0.22 0.41±0.23 0.81± 0.32 
5.10.2.3 Serum concentrations of j3-carotene 
The mean serum ~-carotene concentrations are shown in figure 15. There were no 
significant differences between the 3 groups (CD 0.64±1.01 mg/dl, UC 0.86±1.13 
mg/dl, controls 0.98±1.02 mg/dl), although there was a trend toward lower serum 
levels for CD compared to controls (p=0.20). 
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Figure 15: Serum concentrations of j3-carotene (mg/d/). 

Means of serum concentration are shown with errror bars representing SDs 

2 
1.8 
1.6 
~-carotene 1.4 
cone. 1.2 rnllCD (mg/dl) 1 ~UC 
0.8 
• Controls 
0.6 
0.4 
0.2 

0 

Total CD UC Controls 
p-carotene (mg/dl) 0.72±1.10 0.64±1.01 0.86±1.13 0.98±1.02 
There was no correlation between intakes and serum concentrations (r=-0.008; 
p=0.95) and there was no significant difference in retinol and p-carotene levels of 
those patients who consumed less than the RDA of vitamin A, and those who 
consumed more than the RDA (retinol 0.39±0.22 mg/dl vs . 0.42±0.23 mg/dl; p=0.54, 
p-carotene 0.49±0.86 mg/dl vs. 0.89±1.23 mgldl; p=0.16). Similarly, there was no 
significant differences between the mean serum levels of the 4 different groups of 
intake according to RDA (Figure 16 and Figure 17). There was also no correlation 
between fat intake and serum retinol and/or p-carotene concentrations of subjects 
(r=0.11; p=0.83) and controls (r=-0.20; p=0.67). 
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Figure 16: Serum retinol concentrations for the different vitamin A according to the 

RDA.184 

Means ofserum concentration (mg/dJ) are shown with errror bars representing SDs. If only one 

person was in the group, no SDs are shown 
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Figure 17: Serum fJ- carotene concentrations for the different vitamin A intakes according to the 

RDA. f84 

Means ofserum concentration (mg/d/) are shown with errror bars representing SDs. If only one 

person was in the group, no SDs are shown 
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5.10.3 Vitamin E 
5. 10.3. 1Intake 
Vitamin E intakes are shown in figure 18. Again, all groups had a mean intake of 
greater than 100% of the RDA. Mean intakes of UC, CD and controls were not 
significantly different (CD 308.l9±257.35% RDA, UC 298.23±169.97% RDA, 
controls 260.60±297.50% RDA). 
Figure 18: Vitamin E intake (% ROA). 

Means of intake are shown with errror bars representing 50s 

600 

500 

400 
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The number of people in each group who took in less than the RDA for vitamin E 
were similar (Table 23). 
Total CD UC Controls 
>100% RDA (%) 94 54 (96.43) 40 (90.91) 43 (97 .73) 
100%<RDA<67% (%) 3 0 3 (6.82) 1 (2.27) 
67%<RDA<50% (%) 0 0 0 0 
<50% RDA (%) 3 2 (3.57) 1 (2.27) 0 
Table 23: number of people grouped according to % RDA taken in for Vitamin E 
(RDA=1 Omg184) 
5.10.3.2 Serum concentrations 
The mean a-tocopherol serum concentrations of the UC and CD groups were 
significantly lower than that of controls (UC 6.41±5.54 mg/dl vs. 20.03±5.88 mg/dl; 
p<O.Ol, CD 12.25±7.31 mg/dl vs. 20.03±5.88 mg/dl; p<O.Ol). Furthermore the UC 
concentrations were significantly lower than CD (p<0.01). These concentrations for 
both patients and controls are shown in figure 19. 
There was no correlation between serum concentrations and intakes of subjects 
(r=0.23; p=0.074) and controls (r=0.72; p=O.lO). Similarly, those who took in less 
than the RDA did not have significantly different serum levels to those who 
consumed more than the RDA (8.20±6.54 mg/dl vs. 10.65±7.33 mg/dl; p=0.43). 
(Figure 20). There was also no significant correlation between fat intake and serum 
vitamin E concentrations of subjects (r=0.046; p=O.l9) and controls (r=-0.04; 
p=0.93). 
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Figure 19: Serum concentrations of Vitamin E (mg/d/). 

Means of serum concentration are shown with errror bars representing SDs 
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Figure 20: Serum a-tocopherol concentrations for the different vitamin E intakes according to the 
ROA.184 
Means of serum concentration (mg/dl) are shown with errror bars representing SOs. If there was 
only one person in a group SOs are not shown 
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5.11 Associations with smoking and alcohol 
Although in the group of normal controls, smokers tended to have lower mean serum 
concentrations of vitamin C than non- smokers (1.09±O.52 mgldl vs. 1.46±O.53 
mgldl; p=O.056) (Figure 21), there was no significant association with smoking in 
the IBD patients (O.76±O.63 mgldl vs. O.83±0.45 mgldl; p=O.55) (Figure 22). 
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Figure 21: Serum vitamin C concentrations ofsmokers and non-smokers (Controls) 
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Figure 22:Serum vitamin C concentrations ofsmokers and non-smokers (IBD patients) 
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Mean serum retinol and p-carotene concentrations were not significantly different 

between smokers and non-smokers in both controls (retinol O.76±0.36 mgldl vs. 

O.82±0.31 mgldl; p=O.65, p-carotene O.95±O.63 mgldl vs. O.87±1.10 mgldl; p=O.71) 

and IBD patients (retinol 0.41±O.22 mgldl vs. 0.42±O.23 mgldl; p=O.87, p-carotene 

O.68±l.06 mgldl vs. O.75±1.15mgldl; p=O.79). Similarly, there was no significant 

difference in mean vitamin E serum concentrations for smokers and non-smokers for 

118 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
The Antioxidant Status of Inflammatory Bowel Disease Patients Results 
both patients (11.71±7.59 mg/dl vs. 9.08±6.90 mg/dl; p=0.15) and controls 
(20.80±6.85 mg/dl vs. 19.84±5.73 mg/dl; p=0.69). 
There were no significant relationships between alcohol intake and serum vitamin 
concentrations (p>0.05). 
5.12 Association with age 
There were no significant correlations between any of serum vitamin concentrations 
and age (vitamin C 1-0.04; p=0.75, retinol r=0.04; p=0.78, p-carotene r=0.06; 
p=0.63, a-tocopherol r=0.014; p=0.91). 
5.13 Association with BMI 
There was no correlation between BMI and serum concentrations of vitamin C (r=­
0.09; p=0.48), retinol (r=-0.0043; p=0.97) and p-carotene (r=-0.010; p=0.94). 
Furthermore, there were no significant differences between the serum vitamin 
concentrations of the different weight categories. There was a trend, however, for 
correlation between serum vitamin E concentrations and BMI (r=0.24; p=0.057). 
5.14 Association with duration of disease 
There was no direct relationship between vitamin C levels and duration of disease in 
either CD (r=0.19; p=0.16) or DC (r=0.18; p=0.24). 
However, DC patients who had recently been diagnosed (duration of disease of one 
year or less), had significantly higher levels of a-tocopherol than those who had 
disease for greater than one year (lS.17±1.67 mg/dl vs. 4.S3±3.9 mg/dl; p=0.002) 
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with levels not significantly different to controls (15.67± 1.67 mg/dl vs. 19.81±6.45 
mg/dl; p=0.23) (Figure 23). 
Figure 23: a-tocopherol serum concentrations of those with a duration ofdisease of less than or 
equal to 1 year, and those with a duration ofdisease ofgreater than 1 year 
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On the other hand, mean serum retinol and ~-carotene levels were significantly 
higher in patients with a long history of disease (greater than 10 years) than in those 
with a shorter duration (retinol 0.34±O.l5 mg/dl [0.22-0.45 mg/dl] vs. 0.42±0.25 
mg/dl [0.25-0.71 mg/dl]; p=0.018, ~-carotene 0.32±0.71 mg/dl [0.03-4.35 mg/d1] vs. 
0.51±1.53 mg/dl [0.14-0.65 mg/dl]; p=0.044) (Figures 24 and 25). 
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Figure 24: Retinol serum concentrations for those patients with duration ofdisease greater than 
10 years and a duration ofdisease less than 10 years 
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Figure 25: p-carotene serum concentrations of those with duration ofdisease greater than 10 
years and those with duration ofdisease less than 10 years 
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5.15 Association with relapse rates 
There were no significant associations between vitamin C and p-carotene and relapse 
rates in the previous 2 years (vitamin C t=-0.29; p=O.82, p-carotene r=-0.038; 
p=0.77). Retinol levels correlated significantly with relapse rates in UC patients 
(r=O.52; p=O.OI), but not in CD (r=O.0029; p=0.99). 
Although a-tocopherol seum levels did not correlate with relapse rates, intake of 
vitamin E did correlate with relapse rates foreD patients (t=0.61; p=0.003) (Figure 
26), but not for UC (r=O.19; p=0.40). 
Figure 26: Vitamin E intake (%RDA) for CD patients and relapse rates 
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5.16 	 Association with inflammation and disease 
activity 
There was a trend towards negative correlation between serum vitamin C 
concentrations and ESR (t=-0.27; p=0.068). 
122 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
The Antioxidant Status of Inflammatory Bowel Disease Patients Results 
Expressed catagorically, serum vitamin C concentrations were significantly lower in 
those with ESR of above 20mm1hr, than in those with ESR of below 20mm1hr 
. (0.63±0.39 mg/dl vs. 1.097±0.61 mg/dl; p=0.004). This association appears to be 
mainly associated with CD patients (CD 0.56±0.21 mg/dl vs. 1.10±0.52 mg/dl; 
p<0.02, DC 0.76±0.30 mg/dl vs. 1.01±0.52 mg/dl; p=0.39) (Figure 27). 
There was no direct correlation between serum retinol, ~-carotene and a-tocopherol 
levels and ESR. However, even though serum retinol concentrations were not 
significantly different between those with an ESR of greater than 20mmlhr and those 
. with an ESR ofless than 20mmlhr (CD 0.43±0.22mg/dl vs. 0.43±0.22mg/dl; p=0.95, 
DC 0.38±0.11 mg/dl vs. 0.32±0.20 mg/dl, p=0.45), we did note that serum 
concentrations of retinol were significantly lower in those with an ESR of greater 
than lOmmIhr than in those less than lOmmIhr (0.42±0.23mg/dl vs. 0.38±0.28 
mg/dl; p=0.009) (Figure 28). 
There was no direct association between vitamin C, retinol and a-tocopherol levels 
and CDAI or RBI. However, mean ~-carotene levels were significantly higher in 
patients with active CD (CDAI greater than 200), compared to those who were 
inactive (0.49±0.27 mg/dl vs. 0.39±0.20 mg/dl; p=0.008). 
Figure 27: Vitamin C concentrations of CD patients with an ESR of less than 20 mmlhr, and those 
with an ESR ofgreater than 20 mm/hr 
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Figure 28: Retinol concentrations ofUC patients with ESR less than 10 mmlhr and ESR greater 
than 10 mmlhr 
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5.17 Association with site of disease 
There was no relationship between location of disease and vitamin C, retinol, ~­
carotene and ex.-tocopherollevels in patients with CD. However, ex.-tocopherollevels 
in UC patients with limited disease (proctitis), although significantly lbwer than 
controls (12.62±6.14 mgldl vs. 19.81±6.45 mgldl; p=0.03) were higher than patients 
with left sided disease (6.42±2.60 mgldl vs. 12.62±6.14 mgldl; p=0.05) and total 
colitis (4.11±4.86 mgldl vs. 12.62±6.14 mgldl; p=O.Ol) (Figure 29). Since these 
findings may be a reflection of inflammation, we examined the ESR concentrations 
in UC patients with different sites of disease, and no association was found (proctitis 
11.67±1O.96 mmIhr vs. left sided disease 30.57±25.62 mmIhr; .p=0.26, left sided 
disease 30.57±25.62 mmIhr vs. total colitis 16.31±10.27 mmIhr; p=O.09, proctitis 
11.67± 10.96 mmIhr vs. total colitis 16.31 ± 1 0.27 mmIhr; p=0.50). 
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Figure 29: a-tocopherol serum concentration for sites ofdisease in UC 
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5.18 Associations with drugs 
Use of steroids, salazopyrine (SZP) and AZA did not appear to affect serum levels of 
antioxidant vitamins (Table 24). 
~~----~------------~----~----~ 
125 

Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
The Antioxidant Status of Inflammatory Bowel Disease Patients Results 
Serum 
concentration 
Steroids SZP AZA 
+ - + - + -
Vit C (mg/dl) O.89±O.68 O.82±O.53 O.94±O.53 O.70±0.54 O.99±O.65 O.81±O.53 
Retinol (mg/dl) O.45±O.20 O.44±O.25 O.45±O.24 O.42±O.25 O.36±O.25 O.45±O.24 
~-carotene 
(mg/dl) 
7.16±5.95 8.17±6.26 8.09±5.45 8.42±7.21 5.31±6.57 8.70±6.14 
a-tocopherol 
(mg/dl) 
O.4O±O.49 O.86±1.39 1.20±1.67 1.36±1.34 1.14±2.16 O.76±1.14 
Table 24: Serum concentrations of those on medications (+) and those not on 
medication (-). 
5.19 	 Effect of antioxidant vitamin 
supplementation in patients with Crohn's 
Disease 
5.19.1 Demographic data 
There were no significant differences in sex, age, BMI and smoking habits between 
the normal healthy controls and the patients with CD randomised to receive active 
spray or placebo (Table 25). Duration of disease, disease extent and surgery details 
were also similar in those patients who received active antioxidant spray and those 
who received placebo, and the two groups of patients had similar CDAI, ESR and 
QOL scores at time of entry into the study (Table 25). 
Of the 23 patients who entered the study, 5 (4 placebo, 1 active) patients defaulted 
follow up and 1 patient in the active group refused to continue due to nausea. This 
was recorded as an adverse event, possibly due to the treatment being tested. Seven 
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patients (30%), 3 in the placebo group (25%), and 4 in the active group (36%) were 
withdrawn due to the development of active disease (COAl >200), and 1 further 
patient in the active group was withdrawn due to the development of an abscess 
(Figure 30). 
Controls Placebo Active 
N 23 12 11 
Nmales 8 6 2 
N females 15 6 9 
BMI (kglm") 25.57±3.45 . I 25.44±8.31 25.33±3.96 
Smokers n (%) 5 (22) I 7 (58) 7 (64) 
Age (yrs) 40.91±13.25 39.67±14.26 48.09±16.91 
Duration (yrs) 6.54±5.22 9.8±8.34 
N surgery (small bowel) (%) 2 (17) 2 (I8) 
N surgery (large bowel) (%) 1 (8) 1 (9) 
N surgery (large and small bowel) (%) 2 (17) 2 (18) 
ESR(mmIhr) 28.1±24.S2 30.l3±20.18 
COAl 97.17±56.84 112.40±55.53 
QOL 69.02±12.72 58.05±8.64 
Table 25: Demographic Data 
5.19.2 Vitamin status 
5.19.2.1 Intake 
There were no differences between the intakes of controls and sUbjects. Both 
subjects and controls took in more than 100% of the RDA for all the vitamins (Table 
26)~ and there were no significant differences between the macro-and micronutrients 
in the 6 administrations of the food frequency questionnaire. 
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Figure 30: Organogram ofpatients who were withdrawn from the supplementation study 
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Mean Values Controls (n=23) Placebo (n=12) Active (n=11) 
Vit C (mg) 
VitC%RDA 
173.S±lOS.6 
289.1±176.0 
107.1±118.4 
178.S±197.3 
l1S.2± 93.67 
191.9±IS6.1 
i VitA(mg) 
.VitA%RDA 
863.6±409.4 
lOO.9±49.S4 
974.3±62S.4 
13S.6±89.S4 
I I 84±736.8 
142.6±92.03 
VitE(mg) 
VitE%RDA 
27.24±31..88 
301.S±411.2 
27.318±16.67 
300.17±166.S6 
2S.23±14.74 
299.S±172.6 
Table 26:Mean vitamin intakes in milligrams and % RDA for controls and patients at 
entry into the study 
5.19.2.2 Serum concentrations 
At entry into the study, the serum levels of vitamin C, retinol, ~-carotene and a­
tocopherol of the group ofCn patients who received the supplement were similar to 
those of the patients who received placebo. The serum levels of vitamin C, retinol 
and a-tocopherol in the cn patients was significantly lower than controls (vitamin 
C O.78±O.SI mg/dl vs. 1.26±0.46 mg/dl; p<O.Ol, retinol 0.41±O.23 mg/dl vs. 
O.8S±O.32 mg/dl; p<O.OI, a-tocopherol 16.32±S.SI mg/dl vs. 21.S3±4.74 mg/dl; 
p<O.OI). Furthermore, there was a trend toward lower ~-carotene serum 
concentrations in the CD patients (O.S4±O.39 mg/ell vs. O.87±O.7Smg/dl; p=O.077) 
(Table 27). 
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Serum cone. (mg/dl) Controls 
(n=23) 
Placebo 
(n=12) 
Active 
(n=11) 
Vit C 1.26±Oo46 0.85±0.61 * O.67±0.32* 
Retinol 0.85±0.32 Oo42±0.18* 0.39±0.28* 
a-tocopherol 21.53±4.74 I 16.24±4.66* 16040±6.56* 
~-carotene 0.89±0.75 0.52±0.44 0.60±1.73 
* p<O.01 vs controls 
Table 27: Serum vitamin concentrations at entry into the study 
Serum cholesterol concentrations were significantly lower in the patients compared 
to controls (4.08±0.98 mmolll vs. 5.31±l.09 mmolll; p=0.006) (Table 28). The 
ratio of a-tocopherol to cholesterol, and ~-carotene to cholesterol were not 
significantly different between the groups (p=O.60, p=Oo4) (Table 28). 
Controls 
(n=23) 
Placebo 
(n=11) 
Active 
(n=12) 
Total cholesterol (mmolll) 5.31±l.09 3.93±0.63* 4.00±1.38* 
a-tocopherollcholesterol ratio 1.053±0.21 l.07±Oo41 1.06±0.308 
~-carotene/cholesterol ratio 0.046±0.O43 0.034±0.O25 0.038±0.023 
* p<O.01 vs controls 
Table 28: a-tocopherol, J300earotene and cholesterol concentrations 
Cholesterol concentrations were not associated with BMI (r=0.17; p=0.68), and 
duration of disease (r=-0.02; p=0.91). Similarly, cholesterol concentrations did not 
correlate with ESR (r=-0.24; p=0.38) There was, however, a positive correlation 
between cholesterol concentrations and previous relapse rates (r=0045; p=O.04). 
Furthermore, . those who had relapsed more than once in the previous year, had 
significantly lower a-tocopherol to cholesterol ratios than those who had relapsed 
once or who had not relapsed at all (0.91±0.19 vs. l.02±0.32; p=O.Ol). However, the 
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patients who relapsed during the study, did not have significantly different serum 
cholesterol levels to the patients who did not relapse (3.86±O.87 mmolll vs. 
4.30±1.04 mmolll; p=O.34). 
There were no significant correlations between vitamin intake and serum vitamin 
concentrations for all groups. There were also no significant correlations between 
serum vitamin concentrations and ESR or CDAI. 
There were no differences between the serum concentrations of vitamin C, retinol, 
a-tocopherol and p-carotene of the 2 groups of CD patients who remained in 
remission over the 6 month period (Figures 31-34). Retinol concentrations increased 
over 3 months and were higher at the 3 month visit than at entry into the study, in 
both the actively supplemented (O.74±0.54 mgldl vs. 0.39±O.28 mgldl; p<O.OI) and 
placebo groups (O.70±0.21 mgldl vs. 0.43::1::0.17 mgldl; p<O.OI) (Figure 32). There 
was a significant increase from baseline levels in vitamin E serum concentration at 6 . 
months in the actively supplemented group (22.5±3.96 mgldl vs. 16.4±6.56 mgldl; 
p=O.03), whereas the placebo group remained at baseline levels (16.47±11.04 mgldl 
vs. 16.24±4.66 mgldl; p=O.88) (Figure 34). 
131 

Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
The Antioxidant Status of Inflammatory Bowel Disease Patients Results 
Figure 31: Vitamin C concentration over 6 months. 

Means ofserum concentrations are shown with errror bars representing SDs 
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Figure 32: Retinol serum concentrations over 6 months. 

Means ofserum concentrations are shown with errror bars representing SDs 
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Figure 33: p..carotene serum concentrations over 6 months. 

Means ofserum concentrations are shown with errror bars representing SDs 
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Figure 34: a-tocopherol serum concentrations over 6 months. 
Means ofserum concentrations are shown with errror bars representing SDs 
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5.19.3 Disease relapse 

Relapse rates in the group of patients who received active spray were similar to the 
group who received placebo (Figure 35). At the end of the study, 5 patients in the 
placebo group (42%) and 4 patients in the active group (36%) were still in remission 
(p>O.05). Likewise there was no significant difference in mean CDAI scores or ESR 
values ofthe two groups over the 6 month period (Figures 36 and 37). 
Figure 35: Cumulative proportion ofpatients in remission 
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Figure 36: Mean CDAI over 6 months. 
Means are shown with er"or bars representing SDs 
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Figure 37: Mean ESR (mmlhr) over 6 months. 
Means are shown with er"or bars representing SDs 
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Quality of life scores remained static in both groups over the course of the study 
(Figure 38), and correlated with the CDAl (r=-0.69; p=0.008) (Figure 39). 
Figure 38: Mean QOL score over 6 months. 
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Figure 39: Correlation between CDAI and QOL form 
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At time of entry into the study, the serum vitamin levels of those patients who 
subsequently relapsed were similar to those who remained in remission (vitamin C 
O.89±O.69 mgldl vs. O.64±O.42 mgldl; p=O.77, retinol 0.46±0.32 mg/dl vs. O.33±O.17 
mgldl; p=O.l4, ~-carotene 0.38±O.25 mgldl vs. O.38±O.36 mgldl; p=O.36, vitamin E 
15.05±5.87 mgldl vs. 18.73±5.18 mgldl; p=O.13). Furthermore, at the time of relapse 
and withdrawal from the study, the serum vitamin concentrations of those who were 
withdrawn, were not significantly different to their serum vitamin concentrations at 
entry (vitamin C O.90±O.56 mgldl vs. O.89±O.69 mg/dl; p=O.95, retinol O.69±0.45 
mgldl vs. 0.46±0.32 mgldl; p=O.17, ~-carotene O.38±O.25 mgldl vs. O.63±0.28 
mgldl; p=O.09, vitamin E 18.03±5.46 mgldl vs. 15.05±5.87 mgldl; p=0.49). 
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6. Discussion 
6.1 Nutritional Status and Role of Diet 
The prevalence of malnutrition in IBD as has been reported to be as high as 60-70% in 
some centers. 1,2S4 Yet, despite this, using the BMI as an index of nutritional status, we 
found that in our clinic 47% of our patients were either obese or overweight, and only 
13% were underweight. This may be the result of a greater awareness by clinics such as 
ours, of the nutritional problems associated with IBD, with positive steps being taken to 
avoid nutritional deficiencies, and to maintain remission in patients. Although 44% of 
patients were overweight, the prevalence of obesity was 12% which was similar to our 
control patients (9%). This prevalence however, may still be lower than general 
populationS in' which obesity may affect as many as 33% ofindividtials.2ss 
At the time of interview, 68% of CD patients, and 89% of DC patients were assessed as 
being in clinical remission. It should be noted, however, that obesity affects the calculation 
of the CDAl, and may lead to some underestimation of disease activity in CD.9 Eighty four 
percent ofpatients with CD and 66% of patients with DC had experienced a relapse in the 
past 2 years. 
We were unable to show a significant direct relationship between present dietary intake 
and nutritional status in patients with IBD. Furthermore, nutritional status did not appear 
to relate to duration of disease, or to disease location and extent. Likewise, there was no 
apparent association between nutritional status and relapse rates assessed retrospectively. 
These results indicate that nutritional status in IBD is multifactorial, and also illustrates the 
possible shortcomings of dietary recall as a means of assessing nutrient intake, with both 
under-reporting and over-reporting occuring.2SS Furthermore, although the food frequency 
questionnaire is a valid instrument for assessing intake of antioxidant vitamins136-138 and 
may be of greatest use in epidemiological studies,s6 a single dietary assessment method 
may not be representative of dietary intake if the study population includes several ethnic 
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groups with different dietary habits?56 This stttdy, however, was undertaken in a defined 
patient population, and even though two ethnic groups were included in this study, 
patients were of similar social and economical backgrounds, and tended to consume 
similar foods.9 
Comparing the intakes of the macronutrients of the patients to that of controls it was found 
that patients consumed significantly less protein as a percentage of the energy consumed, 
than controls. In a previous study, 14% of patients complained of intolerance to red meat, 
and 40% said that they avoided eating nuts.9 Similarly, patients often avoid fatty and/or 
fried foods such as sausages, pies, and fried fish possibly as a result of these foods 
increasing diarrhoea in patients with ileal disease.9 Therefore, the patients may be 
consuming less protein containing foods than controls. Furthermore, patients also 
. appeared to have higher caloric intake than controls. This has been reported in other 
studies23,26.32 and may be due to patients increasing their intake while they are well. 26 
Patients also consumed significantly more carbohydrates than controls, a phenomenon 
which has been reported in other studies.23,26,74 This may bea consequence of the 
decreased protein intake, with carbohydrate taken in place ofprotein.23 The relatively low 
protein intake, and high carbohydrate intake, is unlikely to represent an intentional prudent 
diet, considering the relatively high fat intake (36%) of the patients. 
The number of relapses in the last year was significantly associated with fat intake as a 
percentage of energy, and was significantly negatively associated with carbohydrate intake 
as a percentage of energy. Although the incidence of relapse rates was assessed 
retrospectively, the dietary consumption of the patients was considered reasonably 
constant, and therefore representative of the diet prior to relapse. Although we did not 
specifically assess the n6- and n3-fatty acid component of the diet, a normal diet contains 
a predominance of n6-fatty acids,257 and it is possible that an increased intake of n6-fatty 
acids may result in an increased production of inflammatory mediators, such as 
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leukotriene B4, via the arachidonic pathway.13,257,258 Leukotriene B4 has been reported to 
be increased in IBD,257 and therefore, a diet rich in n6-fatty acids may be detrimental to 
IBD patients. This was further supported by Beluzzi' s study where administration of n3­
fatty acids in the form of fish oil capsules significantly reduced the rate of relapse in 
CD.128 The n3-fatty acids (eicosapentaenoic acid) compete with arachidonic acid,26o 
resulting in the production of eicosonoids which are less inflammatory.128 The reduced 
carbohydrate intake in patients with recurrent disease may be a consequence of patients 
avoiding fibrous, carbohydrate rich foods due to obstructive symptoms.22 Since fibre is 
fermented in the gut to produce SCF As which provide an energy source for the 
colonocyte,29 and have proliferative, yet anti-inflammatory effects on ileocolonic 
epithelia,30 a diet low in these fatty acids may predispose IBD patients to relapse. 
As in previous studies,261,262 we noted a high prevalence of smoking in patients with CD 
(50%), which was significantly lower in patients with DC (21 %) and controls (20%), 
(p<0.01). Despite the reported adverse effects of smoking in CD, and benefit in DC,I7,22 
we were unable to demonstrate any significant association between smoking and relapse 
rates in our patients. 
6.2 Vitamin Status 
Mean dietary intakes of vitamin C, vitamin A and vitamin E of patients with IBD and the 
controls were all above 100% of the RDA, with no significant differences between the 
three groups. However, significantly more people with IBD compared to controls 
consumed less than the RDA for vitamin C, with 35% consuming less than the RDA. 
Likewise, significantly more patients with CD consumed less than the RDA for vitamin A. 
Despite the overall adequate intake, serum levels of vitamin C, retinol and a-tocopherol, 
but not p-carotene, were significantly lower in both CD and DC compared to controls. 
There was no direct relationship between serum levels and vitamin intake in both controls 
and IBD patients. This has been previously reported for vitamins A and E.167,211 These two 
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vitamins are fat soluble, and therefore large body stores exist which can be mobilised 
when needed.2oo.216 Decreased intake needs to occur for an extended period of time before 
serum concentrations are affected.33,252 The lack of association between dietary intake and 
serum levels of vitamin E may relate to inaccurate food table estimates of vitamin E and 
variability of the vitamin E content of foods after cooking, storage and processing. 167 
Vitamin E levels may also be affected by regeneration of a-tocopherol by vitamin C,69 
and. possibly retinol. l54 One may have expected a better association between vitamin C 
levels and dietary intake in the control groUp.37 However, serum levels may be more 
acutely affected by recent dietary intake, which may not have been reflected in the dietary 
assessment used. These factors would, however, have affected both controls and patients 
and are therefore unlikely to explain the poor correlation between intake and the low 
serum levels in the IBD patients. The low serum levels in the IBD patients are therefore 
unlikely to relate to dietary intake. 
The effect of changes in serum cholesterol levels on serum levels of a-tocopherol and 13­
carotene in IBD patients was considered, as previous studies have reported lower 
cholesterol levels in IBD patients compared to controls.'4,17S In order to investigate this, 
serum cholesterol levels were assessed in the 23 patients with CD who participated in the 
supplementation study. We found cholesterol concentrations to be significantly lower than 
the control values. The reason for this reduced level is unclear as it does not appear to 
relate to dietary intake, or inflammation, and may reflect an alteration in lipid 
metabolism.263.264 When expressed as the vitamin Elcholesterol ratio, levels of vitamin E 
were in fact no different to control values, suggesting that the apparent low levels of 0'.­
tocopherol merely reflect hypocholesterolaemia in these patients.'4,17S Although it has 
been suggested that the a-tocopherol/cholesterol ratio may be a more accurate index of 
vitamin E status,205,216 this is usually in patients with hyperlipidaemia, and its value in 
hypolipidaemia has not been established.265 
Serum retinol levels are affected by serum protein levels, particularly albumin and RBP.17S 
However, mean albumin levels were normal in our patients, with only three patients, all 
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with evidence of active inflammation at the time, having below nonnal values. Therefore 
the low levels could be not be explained by low albumin levels. 
Age and nutritional status did not significantly affect serum levels. There was however, a 
positive trend between vitamin E levels and BMI. The possibility that the association 
,~ 
between vitamin E and BMI was a consequence of an association with cholesterol was 
considered. However, no direct association between cholesterol and BMI was evident, and 
this is unlikely to fully explain the trend. It has been reported that overweight and obese 
people may have decreased serum antioxidant vitamin concentrations266 due to the 
vitamins being sequestered in increased body fat stores.267 However, the antioxidant serum 
vitamin concentrations in our obese and overweight controls and patients were not 
significantly different to those found in our nonnal weight controls, or patients. Therefore, 
the decreased serum concentrations found in our run patients did not appear to be due to 
the large prevalence ofoverweight in this population. 
Serum vitamin C concentrations of controls tended to be lower in those who smoked 

compared to those who did not smoke. This phenomenon has been previously 

documented/o.182.183.213,268 but was not apparent in our run patients. The reason for this 

discrepancy is uncertain. Smoking is known to be a significant cause of free radical 

production, and therefore antioxidant· depletion, and has been cited as a reason for 

decreased antioxidant vitamin levels.74 It is possible that other factors affecting the serum 

levels of the vitamins in run mask the effects of smoking. Also, despite reports in the 

literature of smokers having ·lower ~-carotene concentrations than non­
. smokers,141,167,206.213 smoking did not seem to affect ~-carotene concentrations in our 

sample. Retinol and a.-tocopherol levels were also not affected by 
smoking.167,206,209,210,213,214 
Other possible causes of the low vitamin C, retinol and a.-tocopherol levels in our patients 
include increased consumption due to active inflammation. Although, like other 
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studies33 ,35.74 we were unable to demonstrate any direct relationship between the serum 
levels of vitamin C, vitamin A and vitamin E and indices ofdisease activity such as CDAI 
and the RBI, these assess other parameters such as abdominal pain, diarrhoea, and general 
well being, which may not directly relate to inflammation. The blood ESR is a more direct 
indication of inflammation and it is interesting that patients with a raised ESR had 
significantly lower levels of vitamin C and retinol. This suggests that serum levels of 
vitamin C and retinol are affected by active inflammation. The effect of inflammation on 
vitamin C serum concentrations has been well documented,269-272 but the mechanism 
behind this is not clear.272 It is thought that in active inflammation serum ferritin falls 
(negative acute phase response). This results in the amount of free iron increasing due to 
inadequate binding capacity in the plasma. Under these circumstances vitamin C reacts 
with the iron, and may form free. radicals. In order to prevent free radical formation, and 
further oxidant mediated damage,271,272 neutrophils may increase their uptake ofvitamin C 
from serum.270 This increased uptake may also help improve the antioxidant function of 
the neutrophil. 270 Furthermore, the vitamin C may be transported to the tissue site where it 
is needed, thereby decreasing the circulating serum concentrations.270 Vitamin C is also 
utilised to regenerate vitamin E.69 The reduction in retinol levels with acute inflammation 
may be consequent to a reduction in RBP, also as part of the acute phase response,270.271 as 
well as retinol utilisation to regenerate vitamin E.155 The apparent lack of effect of active 
inflammation on vitamin E levels may be explained by the synergism between vitamin C 
and vitamin E,69.14~,152 and retinol and vitamin E,155 where in active inflammation, vitamin 
C and retinol are utilised to regenerate. vitamin E, thereby normalising vitamin E 
levels.38,155 
The acute phase response has been associated with a number of other metabolic 
abnormalities. These include decreased albumin and cholesterol concentrations,269 which 
can affect serum vitamin levels, particularly ofvitamin A and E, which are protein or lipid 
bound. Although active inflammation does appear to result in decreased levels of vitamin 
C and retinol, it should be noted that serum levels were also low in patients with no 
evidence of active inflammation indicating that other factors are also responsible. 
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Site of disease, such as colonic, ileo-colonic and ileal involvement did not appear to 
influence the serum levels of the vitamin in patients with CD. Similar results were shown 
in a study by Kuroki et aI, in 1993.35 However, extent ofdisease did appear to affect serum 
levels of a-tocopherol in patients with UC. Serum levels of a-tocopherol in patients with 
disease restricted to the rectum although still significantly lower than controls, were 
significantly higher than those with disease in the left colon or with total colitis. The colon 
is a dynamic organ which is particularly prone to oxidative stress. Most of the antioxidant 
enzymes in the colon are located in the lamina propria. This leaves the mucosa with a 
relative deficiency,110 and therefore the colon is at risk of oxidant mediated damage, and 
depletion of antioxidant vitamins. Vitamin C, retinol and l3-carotene are antioxidants 
which are used preferentially in order to spare vitamin E, the most potent antioxidant. Is1 
Therefore, since vitamin C, retinol and l3-carotene concentrations are low, and the colon is 
inflamed, vitamin E is being utilised to neutralise free radicals. Furthermore, the greater 
the extent of disease, the greater the free radical production and the more vitamin E will be 
used. These factors may explain the association between vitamin E levels and the extent of 
colitis. The role of serum cholesterol levels in UC was not investigated in this study, and 
• further study is required in this regard . , 
Alpha-tocopherol serum concentrations in UC patients with recent onset of disease (less 
than one year), were significantly higher than those with a longer duration of disease. On 
the other hand, serum retinol and l3-carotene levels appeared to be higher in both CD and 
UC with disease of longer duration (>10years). The reason for these associations is not 
clear. It has been shown, however, that vitamin A decreases with active inflammation36 
and it is possible that patients with a recent onset of illness may have experienced more 
active disease, than that in whom the condition is longstanding and stable.· As regards the 
serum levels of a-tocopherol, in investigating the reason for the apparent decrease in 
levels with activity of disease in UC, it would be important to assess the effects of disease 
duration on serum cholesterol levels. 
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• 
The relationship between the antioxidant vitamins and relapse rates was also considered. 
Patients with UC who had relapsed in the previous 2 years tended to have higher levels of 
retinol, and those with CD tended to have higher levels of a-tocopherol. There was no 
apparent association between relapse rates and vitamin C and l3-carotene. However, in this 
aspect of the study, the rate of relapse was assessed retrospectively, and the present serum 
levels of vitamins may not reflect the levels prior to relapse. In fact the higher levels of 
retinol and a-tocopherol may reflect an adaptive response following the episode of acute 
inflammation.36 This was shown in a study by Ramakrishna et aI, when vitamin A 
decreased with active disease, but increased again, when the disease was treated. 
Furthermore, when levels had returned to normal, they were in fact non-significantly 
higher than controls.36 
6.2 Effect of supplementation 
In order to prospectively study a group of patients with IBD and to investigate the role of 
antioxidant vitamin supplementation, a double-blind, placebo controlled study was 
performed in a group of patients with CD. The study was designed to investigate the 
effect of supplementation of antioxidant vitamins, given as a buccal spray, on subsequent 
relapse rates. The supplemental spray contained 100% RDA for vitamin A, and E, and 
10% for vitamin C and l3-carotene. We elected to use the apparent rather modest dose, as 
when the supplementation was added to the normal diet, patients were in fact consuming 
greater than 200% of the RDA for vitamin A and 400% for vitamin E, and the dose used 
complied with the manufacturers recommendations. Furthermore, studies have indicated 
that carotenoids in large doses may be associated with adverse effects including an 
increased risk ofcertain cancers.174,2S3 We also chose to use a multivitamin supplement as . 
antioxidant vitamins act synergystically, 149,ISS. and since we had shown that our IBD 
patients have lower serum antioxidant vitamins for all the v~tamins tested, it seemed that 
a combination of these vitamins was more likely to have a beneficial effect than anyone 
vitamin alone. Furthermore, in supplementation trials on pancreatic, HN and cancer 
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patients, multivitamin supplements have been used with beneficial effect,249,25o while 
single vitamin supplementation trials in IBD have shown no beneficial effects. 179,273 
Antioxidant supplementation has been reported to be beneficial in several diseases, 
including pancreatitis, cardiovascular disease, cancer, and HIV. A number of different 
supplementation dosages have been used, and the ideal supplementation dose, as well as 
which vitamins need to be supplemented, remains controversiaL247,274 In a 20 week 
double-blind dummy cross over trial, Uden et aI, 1990, reported that a supplement 
containing 600J..lg organic selenuim, 9000ID p-carotene, 270IU vitamin E, 2g methionine, 
and 0.54g vitamin C aided in the therapy of recurrent (non-gallstone) pancreatitis and/or 
pancreatic pain?49 In cardiovascular disease, Enstrom et aI, showed an inverse 
relationship between vitamin C supplementation of at least 50mglday and risk of 
mortality,275 and Vita et al reported that vitamin C doses at higher than the RDA are 
beneficial to subjects with deficient intakes or to patients with significant coronary artery 
disease.276 In the CARET study, however, in which 18 314 smokers, former smokers, 
and workers exposed to asbestos were randomised to receive 30mg p-carotene per day 
and 25 OOOID of retinol in the form of retinyl palmitate or placebo, no effect on 
cardiovascular disease was found. 175 Similarly in the ATBC lung cancer prevention study 
where 29 133 male subjects were randomised to receive a supplement of p-carotene 
(20mglday) or a-tocopherol (50mglday) alone, or both, or placebo, there was no 
reduction in incidence in lung cancer after 5-8 years of dietary supplementation.174 In 
fact, there seemed to be an increase in the incidence of lung cancer in those on the p­
carotene supplement. 174 In HIV, supplementation studies using vitamin A at a daily dose 
of 5000IU retinyl palmitate and 30mg p-carotene, showed no effect on reducing overall 
mother-to-child transmission of HIV.277 Similarly in a study using a p-carotene 
supplement of 180mglday for 4 weeks in patients with normal baseline serum levels of p­
carotene and vitamin A, there was no effect on CD4 lymphocyte count or plasma HIV 
RNA copy number.278 Furthermore, a supplement containing 10 SOOU vitamin A, 300mg 
vitamin C, 300mg vitamin E, 150ug selenium, and 200mg zinc, taken twice daily with 
800mg albendezole, has been shown to have no effect on diarrhoea or morbidity or 
mortality in HIV?79 However, in a trial of49 HIV positive patients randomised to receive 
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supplements of both DL-a.-tocopherol acetate (88IU daily) and vitamin C (1000mg 
daily) or placebo for 3 months, oxidative stress decreased significantly in the 
supplemented group as compared to controls, and there was a trend to reduction in viral 
load.250 
Our supplementation provided similar ~-carotene (2Smg) but less vitamin E (1 Omg), 
vitamin C (6mg), and retinol (lOOORE) than other supplementation 
trials.174,1 77,250,275,276,279,280 Supplementation resulted in a significant increase in serum 
vitamin E levels, to a level not different to control values. There was also a significant 
increase in retinol levels, but this increase was noted in both the actively supplemented 
group as well as the placebo group, and is therefore unlikley to be solely the result of 
supplementation. There was no statistical change in vitamin C and ~-carotene levels over 
the course of the study. 
In view of the low dose of vitamin C in the supplement, and the normal serum levels of 
~-carotene in the patients, it is perhaps not surprising that the serum concentrations of 
these vitamins were unaffected during the course of the study. However, a number of 
factors may have affected the absorption and utilisation of vitamins in our patients. The 
mean BMI ofour trial subjects was in the overweight range, there were a large amount of 
smokers in the group, and serum concentrations of the vitamins were significantly lower 
than controls at baseline. Nierenberg et aI, reported that nonsmokers, lean people and 
those with higher baseline serum concentrations have larger increases in plasma 
concentrations with supplementation.251 Therefore the response of our subjects to the 
supplement may have been retarded. Furthermore, the levels of vitamins in the 
supplement may not have been adequate for a popUlation who may be malabsorbing the 
vitamins from their diets,251 and larger doses, as in other supplementation studies, I 77,249,250 
should be considered for further investigation. There is however; large inter- and intra­
individual variability in response to vitamin supplementation, and in a study of HN 
patients using a supplement containing 10 SOOU vitamin A, 300mg vitamin C, 300mg 
vitamin E, and ISOug selenium and 200mg zinc, the serum levels of those in the 
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supplemented group, also did not rise significantly when compared to placebo?79 In a 
study by Wright et aI, 1985 in which 50 OOOU of vitamin A per day was given to 86 CD 
patients in remission, a significant difference in serum concentrations between the 
placebo group and the supplemented group was only noted after 5 months.179 
Furthermore, serum level measurements of these vitamins may _not be an adequate 
measure of the effect of supplementation. Albanes et aI, showed that adipose tissue 
concentrations of retinoic acid increased, in patients whose plasma or serum retinol levels 
did not change in response to a ~-carotene supplement.141 Furthermore, in one study in 
which high doses of ~-carotene were fed to preruminent calves, vitamin A was found to 
have accumulated in the liver.281 Leukocyte vitamin C concentrations, which reflect 
tissue levels, may also have been a more accurate measurement ofvitamin C.70 Moreover, 
in view of the method of delivery, it was difficult to assess compliance in our subjects, as 
we could not do a pill count. The-default rate for the trial was high and several of our 
patients were lost to follow up. 
Our study investigated the serurri vitamin levels of CD patients during supplementation. 
We did not directly examine the absorption of the supplement, the metabolism of these 
vitamins in this group of patients, the consumption of these vitamins in the inflammatory 
process, or their excretion. Future studies looking at these aspects of antioxidant vitamin 
metabolism, in this popUlation, are required. 
In our study, results indicated similar relapse rates in the patients who received active 
antioxidant spray compared to placebo with 4 patients· in the active group relapsing 
compared to 3 patients in the placebo goup. On an intent to treat analysis 4/11 (36%) of 
those receiving antioxidant were still in remission after 6 months compared to 5/12 (42%) 
of those receiving placebo. At time of entry into the study, the serum concentrations of 
the vitamins of those patients who subsequently relapsed were similar to those who 
remained in remission, and therefore gave no indication of risk of relapse. There was also 
no significant difference in CDAI scores between the 2 groups over the 6 month period. 
QOL scores were also similar. 
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It is possible that the doses delivered in our spray supplement may have been insufficient 
to have an effect on relapse rates. However, a previous study by Wright et aI, using a 
vitamin A supplement of 55 000 IU BD (550% RDA) was also unable to show any effect 
on relapse rates. 179As regards supplementati~n with a-tocopherol, when reflected as the 
a-tocopherol/cholesterol ratio, the levels in our CD patients were similar to controls, and 
the patients may in fact not have been deficient initially. Furthermore, we have also noted 
that increased dietary intake of vitamin E was in fact associated with an increased relapse 
rates in CD. It is therefore possible that increasing the vitamin E intake may actually be 
detrimental in CD. The mechanism behind this is unclear, but may be related to the role 
of vitamin E in apoptosis. In CD, apoptosis has been reported to be decreased compared 
to controls,54 and may be an important pathogenic mechanism in the disease. 55 Vitamin E 
has also been shown to impair apoptosis,229 and it is possible that an increased intake of 
vitamin E may actually perpetuate the inflammation in the disease. 
The primary objective of our study was to investigate the effect of an antioxidant vitamin 
supplement on relapse rates in CD. Patients who relapsed were therefore discontinued 
from the study. The development of active disease during the study, determined by the 
CDAI, or the development of complications such as abscesses, did not appear to 
significantly affect the serum levels of the vitamins, and the levels at the time of relapse 
were similar to levels at the time of entry. The effect of subsequent therapy of active CD 
on vitamin levels was not assessed. 
These results indicate that supplementation of vitamin A and E does not effect disease 
relapse rates in CD, and suggests that the low serum levels noted in patients may be a 
consequence ofthe chronic inflammatory process, and not necessarily the cause. 
Considering the relatively small numbers of patients recruited into our study, one should, 
perhaps, be cautious in interpreting the results, and the trial should rather be considered a 
pilot study. However, considering our results, and the proportion of· patients who 
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remained in remission over the duration of the study, we calculated that in order to 
demonstrate a significant difference between the two groups, a sample size of 712 
subjects would have been required to demonstrate an advantage, in favour of placebo! We 
are therefore satisfied that there is no evidence that the supplementation at the doses used, 
and with the delivery method utilised, offered any advantage to CD patients. To our 
knowledge, the role of supplementing vitamin C to patients with IBD has not been 
reported, and further research on the role ofvitamin C in IBD is indicated. 
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7. Conclusion 

Both Crohn's disease and ulcerative colitis are associated with decreased serum 
levels of vitamin C, retinol and a.-tocopherol, but not p-carotene, despite adequate 
dietary intakes. The cause of these reductions is likely to. be multifactorial, with 
active inflammation directly affecting the levels of vitamin C and retinol, and a.­
tocopherol levels affected by disease extent in UC, as well as serum cholesterol 
concentrations. Nutritional status and smoking did not appear to significantly affect 
the vitamin levels in IBD patients. Supplementation of vitamin A and E did not 
appear· to influence disease relapse rates in CD, suggesting that low levels of 
vitamins may be ~ consequence and not necessarily the cause of the inflammatory 
state. 
7.1 Recommendations for future studies 
1. 	 This study assessed the role of antioxidant supplementation in preventing relapse in 
, 
Crohn's disease. The effect in active disease was not assessed and should be 
evaluated in further studies. Furthennore, the· effect of higher doses of antioxidant 
vitamins should also be considered. 
2. 	 The effect ofantioxidant supplementation in UC should also be assessed. 
3. 	 The role of vitamin C appears to be central to the anti-inflammatory process, both 
with its specific antioxidant propertIes, as well as in regeneration of a.-tocopherol. 
The role of vitamin C in treating active disease, as well as in preventing relapses 
should be assessed" 
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APPENDIX 1: BASELINE CASE REPORT FORM 
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CRF for baseline subjects 
Name: 
Age: 
Diagnosis: 
Diagnosis date: 
Duration: 
Folder no: 
Smoking: 
Gender: mlf 
Relapses in last 2 years: 
Surgery in last 2 years: 
Medications: 
Anthropometry 
Weight: Height: BMI: 
TSF: 1 2 3 average 
MAC 1 2 3 average 
Food Frequency: 
Cals: 
%prot: 
%fat: 
%CHO 
% alcohol 
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· APPENDIX 2: INFORMED CONSENT FORM 
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The tenn "Inflammatory Bowel Disease" (IBD) encompasses two diseases, Crohn's 
Disease and Ulcerative Coltits. The exact cause of these diseases remains unknown. 
However, recent research suggests that reactive molecules known as free radicals, which 
are produced in the tissues, may playa role in many inflammatory conditions including 
IBD. Certain vitamins, such as Vit A, E and C have antioxidant properties, and may help 
to decrease the level of free radicals. This may be beneficial in reducing the inflammation 
in IBD. 
Therefore, the aim ofthis study is to: 
1. 	 assess the antioxidant status of patients and to relate this to nutritional status and 
disease activity 
2. 	 assess the effect of supplementation of antioxidant vitamins, especially Vit A, C, E 
and B-carotene, on serum levels, disease activity and quality of life. 
This study will require subjects to undergo monthly interviews and blood tests to 
ascertain vitamin intake, as well as taking a vitamin supplement. 
I ......................................................... , hereby give my infonned consent to be a subject in 
the aforementioned triaL 
Signature ............................. . 

Date .................................. . 
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APPENDIX 3: DIETARY QUESTIONNAIRE 

Food Frequency 
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FOOD FREQUENCY QUESTIONNAIRE 
TYPE 
MILK 
TIMES 
PER 
WEEK 
1-2 AMOUNT 
TIMES 
PER 
MONTH 
PREPARATION 
FUCC....--_·....-·····+·············"····...···l······"······-"....."-.................. ···"-·········"···········",,·_"···"·,1"""·",,""···-··"-"---I--------------1 
CREAM 
"LOW'FAT/2%-­ .r-----/-."-"...--."-...-".......-".....-"..---+....-----------~ t-SKIM.."-· .._"--!'--......".."' ..·"·"-·t 
ICE-CRE ---~---+---~-----~-------------~ 
·_--"·"....·..--1------1----"·--"·.."--"-1 .................,...·"·_---+-----­--~-- ..--.......
""SORBET 
-FROZEN 
DESSERT 
YOGHURT 
LOW FAT 
--1--....._--"­ ...."--"--.."...".........".."......­ ..........."............."-.....-"..f------. ---------1 
FAT FREE --!-----!--"....­ ..."-....."­ .......­ .....­ ....---."f--------------! 
i YELLOW 
I CHEESE 
! COTTAGE 
CHEESE 
EGGS 
FRIED 
"'i30ILED­CpOACHE=-D-....--f-'..·..·"......·....""·...·""·....,L-....-,,·""·....--"-" ...-""""".-"........"".....""""... ,.. ,­ ""....."",,....,,"""""""""" """.1-------­
RED MEAT 
EGMUTTON 
MINCE 
MEAT 
CHICKEN
-WITH SKIN""­ -"""""""""._ .... 
WITHOUT ·--~.... ·"""" ..........··-li .... --....-·~---···..-·-··..·...···+-----------,....... 
SKIN 
LIVER 
iPORK 
POLONY 
VIENNAS 
BOEREWORS 
VEG 
CARROTS~_+---"....4_.._ ...··-"...-··.... I·,,""".............­ ....·--1--_--·....I---__.._______ ~-.-.--+-""-"""""--.........""..".."l ......-.-----+-­
POTATOES 
POTATO 
---I-"-."....-.-...........f------" "-·-"--"..·-"",,......l-----....­ ..--...."·----·........4 
f,,-::::-:=-:::-....--·"--I""--,,·-.... 
GEM 
-".",,_.__.."-_.."-----_ ....__._.......""."...."-"..1--------------­
SQUASH "....".. _""-" "_..."- ".____.1__...._"""..._
'""SPINACli"-'"- --""""",,..... 
(COOKED)
I-MlXEDVEG........ 1---""'"-"-" 
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_._,-_.__..._--,.--_................-................_-..._..........-......­ .---­r----~---.---..-.--......., 
L~~d~=.·=·::-=..~.~--i+-.---....·-.--.-.-'-.-~= =::~=~::=~:::.:::~~:::. ~::::~=::==..=:--.I-----------.--.­
GREEN 
BEANS 
~S----"- ..·· ---_...-_.._"-"". --"._..._........__.... '---'''-''''---'-­ -_._..._---_.....__.........­
"CABBAGE ... ­ .. _-... 1--..... ---1--------------1 
-CORN/ 
MIELIES 
FRUIT 
MEIO=N~--..-..+·-·"-..·"""..·..·..---+··-....·--+----+---..·..·-..·..­......·....­..1------­
ORANGESIORANGE-- ­ ....------ ..........................._._._ ....._ ....___-1-_..__......._.......1-_______ 
I JUICENAARTIES ...................................................­ ...................­ ................--...................._.........­ ..................._-.-1--...._ .. 
"FEACHES ........­ ..._.._.._.__.--............_..__.--.._-_....-.. -""""~---------l 
r-wATER- .--... -..-._------_.....­ "'-"----"-"­ '--------_.­
MELON
,'" APPLES-'''- ......._."'n_n..."""""__ ,,~. 
~..·BANANAS-·-- _ ............_....... \---.__.... 
-'P]Ir:NES'''-­ ·---+----1-----··....·+-----------------1 
"RAISINS' 
·....·GRAPEFRUItc-l------......I....--.. 1............·....·..··_......_ ..·­ ·..----............·..1--.---­..----..--.-1 
i TOMATO 
SAUCE 
OIL 
VINEGAR 
DRESSING 
MAYO 
CHUTNEY 
PIZZA 
POTATO 
CHIPS 
NUTS 
~DY
= SLAP CHIPS 
i CEREAL 
i RICE 
i WHITE 
• BROWN 
PASTA 
BREADI 
ROLLS 
WHITE 
WW 
RYE 
CEREAL 
CHOCOLATE 
SWEETS 
PUDDINGS 
JAM 
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SUGAR 
TEA 
COFFEE 
ROOIBOS 
ALCOHOL 
~ruNKS 
FRESH FRUIT 
MIX A 
DRINKr-OTHER-···--···· - ....._....................._......_........_........_....__.........­.................._..................  
! BUTTER 
· OIL 
CREAM 
CREAMER 
MARG 
r----------------------.­
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APPENDIX 4: CLINICAL ASSESSMENT INDEX 

Crohn's Disease Activity Index (CDAI) 
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I 
!Abdominal pain rating: (O=none; 1=mildj 2=moderate; 3=severe) I 
ILiquid/soft stools: (days one it seven In consecutive blocks) 
ItotaI1:.II_ 
l1li III II II··. IIIii Itota'2:1. 
iGeneral well-being: (O=generally well,1=slightly under par, 2=poor, 3=very poor, 4=terrible) I 
III II II II • II Itotal3: Ifill 
lComplicatlons 0 Arthritis/Arthralgia. 
o liritis/Uveitis I 
U IErythema NodosumlPyoderma Gangrenosum/Aphthous StomaiitlS--l 
o Itotal4: I 
C IOther fistula I 
o IFever over 37.8 degrees celsius during the past week 
iUse of diphenoxylate,loperamide,()r()~~er opiates for diarrhoea Itotal 5: 11111 
IAbdominal mass: O",Il(me, 2::::rquestlonable, 5=defiliite II. Itotal6: II.. 
[Haematocrit: J IRtil Itotal7: II_ 
~dard weight: II_ Ikilograms!Body weight: 
, CROHN'S DISEASE ACTIVITY INDEX (COAl) is: 
Todays date: I Thursday, October 26, 
2000 
IData entered by: i 
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APPENDIX 5: CLINICAL ASSESSMENT INDEX 

Harvey Bradshaw Index (HBI) 
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None 
Mild 
Moderate 
Severe 
General well being 
Perfect 
Very good· 
Good 
COLITIS ASSESSMENT 
Diarrhoe ( no. of daiJy stools ) 
0-2 o 
3-4 1 
5-6 2 
7 - 9- 3 
10 4 
Nocturnal Diarrhoea 
No o 
Yes 1 
Visible blood in stools ( % or movements) . 
0% o 
<50% 1 
>50% 2 
100% 3 
Faecal Incompetence 
No o 
Yes 1 
Abdominal pain/cramping 
o 
1 
2 
3 
o 
1 
2 
3 
4 
5 
nUUOlllUnaI Tenderness 
o 
and localised 1 
to moderate and diffuse 2 
or rebound 3 
for antidiarrhoels 
o 
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APPENDIX 6: QUALITY OF LIFE ASSESSMENT 

The SF- 36 quality of life form 
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SF-36 HEALTH SURVEY 
INSTRUCTIONS: This questionnaire asks for your views about your health, how you feel and how well 
you are able to do y()ur usual activities. 
Answer every question by marking the answer as. indicated. If you are unsure about how to answer a 
question, please give the best answer you can. 
1. 	 In general, would you say your health is: 
(circle one) 
Excellent. ................................................................................................................ 1 
Very good ............................................................................................................... 2 
Good ...................................................................................................................... 3 
Fair ......................................................................................................................... 4 
Poor ........................................................................................................................ 5 
2. 	 Compared to one week ago, how would you rate your health in general now? 
(Circle one) 
Much better now than one week ago .................................................................... 1 
, 
Somewhat better now than one week ago ............................................................ 2 
About the same as one week ago ......................................................................... 3 
Somewhat worse now than one week ago .......................................................... .4 
Much worse now than one week ago .................................................................... 5 
. _.. - ------­
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3. The following questions are about activities you might do during a typical day. Does your 
health now limit you in these activities? If so, how much? 
(circle one number on each line) 
Yes, Yes, No, Not 
ACTIVITIES Limited Limited Limited 
A Lot A Little At A" 
1a. Vigorous activities, such as running, lifting heavy 2 3 
objects, participating in strenuous sports 
1b. Moderate activities, such as moving a table, pushing 2 3 
a vacuum cleaner, bowling, or playing golf 
c. Lifting or carrying groceries 1 2 3 
d. Climbing several flights of stairs 1 2 3 
e. Climbing one flight of stairs 1 2 3 
f. Bending, kneeling or stooping 1 2 3 
g. Walking more than one kilometre 1 2 3 
h. Walking half a kilometre 1 2 3 
i. Walking 100 metres 1 2 3 
j. Bathing or dressing yourself 1 2 3 
4. During the past week, have you had any of the following problems with your work or other regular 
daily activities as a result of your physical health? 
(circle one number on each line) 
YES NO 
a. Cut down on the amount of time you spent on work or other 
activities 
1 2 
b. Accomplished less than you would like 1 2 
c. Were limited in the kind of work or other activities 1 2 
d. Had difficulty performing the work or other activities (for 
example, it took extra effort) 
1 2 
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5. 	 During the past week, have you had any of the following problems with your'work or other regular 
daily activities as a result of any emotional problems (such as feeling depressed or anxious)? 
(circle one number on each line) 
YES NO 
a. Cut down on the amount of time you spent on work or other activities 1 2 
b. Accomplished less than you would like 1 2 
I c. Didn't do work or other activities as carefully as usual 1 2 
6. 	 During the past week, to what extent has your physical health or emotional problems interfered with 
your normal social activities with family, friends, neighbours, or groups? 
( circle one) 
Not at all ........................................................... : ................................................... , 1 
Slightly ........ , .............................. ,. , ........................ ,. ,. ,., ................................. , ......... 2 
Moderately ............................................................................................................. 3 
Quite a bit. ............................... , .............................................................................. 4 
Extremely .............................. ,., ........ "., ... , ....... , ...................................... , .......... : .... 5 
7. 	 How much bodily pain have you had during the past week? 
(Circle one) 
No bodily pain ........................................................................................................ 1 
Very mild .......................................... , ................... , ........ , .... , ............ , ...... , ............... 2 
Mild ......................................................... , ... , .......................................................... 3 
Moderate ...... , ....... , ................ '., ...... , ..................................................... , ................. 4 
Severe ..................... , ....... , ...................................................................................... 5 
Very severe ..... , ....................... " ............................................................... .; .... , ....... 6 
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8. 	 During the past week, how much did pain interfere with your normal work (including both work 
outside the home and housework)? 
(circle one) 
Not at all ................................................................................................................. 1 
A little bit ................................................................................................................. 2 
Moderately ............................................................................................................. 3 
Quite a bit. ............................................................................................................... 4 

Extremely ............................................................................................................... 5 

9. 	 These questions are about how you feel and how things have been with you during the past week. 
For each question, please give the one answer that comes closest to the ay you have been 
feeling. How much of the time during the past week ­
(circle one number on each lin~ 
All 
of the 
Time 
Most 
of the 
Time 
A Good 
Bit of 
the Time 
Some 
of the 
Time 
A Little 
of the 
Time 
None 
of the 
Time 
a. Did you feel full of life? 1 2 3 4 5 6 
b. Have you been a very 
nervous person? 
1 2 3 4 5 6 
c. Have you felt so down in 
the dumps that nothing 
could cheer you up? 
1 2 3 4 5 6 
d. 
e. 
Have you felt calm and 
peaceful? 
Did you have a lot of 
energy? 
1 
1 
2 
2 
3 
3 
4 
4 
5 
5 
6 
6 
f. Have you felt down? 1 2 3 4 5 6 
g. Did you feel worn out? 1 2 3 4 5 6 
h. Have you been a happy 
person? 
1 2 3 4 5 6 
i. Did you feel tired? 1 2 3 4 5 6 
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10. 	 During the past week, how much of the time has your physical health or emotional problems 
interfered with your social activities (like visiting with friends, relatives, etc.)? 
(circle one) 
All of the time ......................................................................................................... 1 
Most of the time ..................................................................................................... 2 
Some of the time .................................................................. : ................................. 3 
A little of the time ................................................................................................... 4 

None of the time .................................................................................................... 5 

11. 	 How TRUE or FALSE is each of the following statements for you? 
(circle one number on each line) 
i 
Definitely 
True 
Mostly 
True 
Don't 
Know 
Mostly 
False 
Definitely 
False 
I a. I seem to get sick a little 
easier than other people 
1 2 3 4 5 
b. I am as healthy as anybody 
I know 
1 2 3 4 5 
c. I expect my health to get 
worse 
1 2 3 4 5 
d. My health is excellent 1 2 3 4 5 
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APPENDIX 7: SERUM VITAMIN ANALYSIS 

Colourometric vitamin C analysis242 
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Vitamin C analysis242 
Blood was analysed within 3 hours of being drawn, as stated in the methodology 
section (4.3.1.1). 
Reagents 
All reagents were supplied by Merck NT Laboratory Supplies 
1. Vitamin C 
2. Metaphosphoric acid 
3. Thiourea 
·4. Cupric sulphate (anhydrous) 
5. 2,4 Dinitrophenylhydrazine 
6. Sulphuric acid 
Preparation of reagents for blood analysis 
Sulfuric acid solutions of 12molIL and 4.5mollL were prepared in advance by adding 
650ml and 250ml of sulfuric acid to cold double-distilled water. The concentrated 
sulfuric acid was stored at 4°C. 
A copper sulfate solution (O.6g/dl) was also made up by dissolving O.6g of anhydrous 
copper sulfate solution in double-distilled water, and diluted to a final volume of 
lOOmIs. 
Each month, a thiourea solution (5.0gldl) was made by dissolving 5g of thiourea in 
double distilled water and diluted to 100ml. This was also stored at 4°C, and discarded 
after one month. 
Once a week, 2,4-dinitropheylhydrazine reagent, 2.0gldl was made. 5g of 2,4­
dinitrophenylhydrazine was dissolved in sulfuric acid (4.5mollL), and diluted to a 
final volume of 250ml with the 4.5moVI sulfuric acid. This was stored at 4°C 
overnight, and filtered the next day. The filtered solution was also stored at 4°C, and 
was discarded after a week. 
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Similarly a solution of dinitrophenylhydrozine-thiourea-copper sulfate (DTCS) 
reagent was prepared once a week by the addition of Sml of the thiourea solution, Smi 
of the copper sulfate solution and 100ml of the 2,4-dinitrophenylhydrazine solution. 
This was stored in a glass container in the fridge at 4°C for no longer than a week, 
when it was discarded. 
Apparatus 
Beckman 2S spectrophotmeter and recorder 
Analysis 
• 
Once the serum was centrifuged and stored away from light and air in foil covered 
sealed test-tubes, in the fridge at 4°C, a solution ofmeta phosphoric acid (6.0gldL) was 
• 
prepared by dissolving lS.0g of metaphosphoric acid in double-distilled water, and 
bringing it to a final volume of2S0mL This was prepared directly before use. I 
• 
Standards 
The ascorbic acid stock standard was then prepared by dissolving 2Smg of ascorbic 
acid in the metaphosphoric acid and bringing it to a final volume of SOmt. An 
intermediate standard was then prepared by pipetting Smls of this solution into a 
volumetric flask, and diluting it to SOml to make a S.Omgldl solution. 
Analysis of vitamin C 
Once this task had been accomplished O.S ml ofplasma was pipetted into 2.0mI of the 
metaphosphoric acid in a 13 X 10mm test tube. This was mixed well on the vortex 
mixer and then centrifuged for 10 minutes on 2S00g. Each sample was prepared in 
duplicate. 
While the samples were spinning working standards were prepared by pipetting the 
following amounts of intermediate standards into test tubes (see table below). 
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I 
Working Standard Amount intennediate Amount metaphosphoric I 
concentration (mgldl) Standard (ml) acid (ml) 
0.10 0.05 2.45 
0.4 0.2 2.3 
0.8 0.4 2.1 
1.2 0.6 1.9 
2.00 1.0 1.5 
3.00 1.5 2 
1.52.04.00 
Once prepared, these standards were then vortex mIxed to ensure homogeneity 
Once prepared, 1.2 mls of each working standard was pipetted into teflon lined test 
tubes, in duplicate. Furthennore, 1.2ml of metaphosphoric acid was added to two of 
these test tubes as blanks. Once centrifuged, 1.2ml of the clear supernatant of the 
samples was also pipetted into teflon-lined test tubes. 
O.4mls of the DTCS reagent was added to each tube. Caps were placed on the test 
tubes, and they were all vortex mixed, and then placed in a water bath at 37°C for 3 
hours. 
The test tubes were removed fonn the water bath after 3 hours, and placed in a ice­
bath for 10 minutes. 2mls of cold 12moVL sulfuric acid was then added while vortex 
mixing. The temperature of the samples did not exceed room temperature at any time. 
The absorbence of samples was read on a spectrophotometer at 520nm. Each working 
standard concentration was plotted on a graph against the absorbence, creating a 
standard curve. Sample absorbence readings were then used to plot the samples on the 
standard graph. The concentrations found from the graph were then multiplied by 5, 
in order to correct for the dilution of the serum by metaphosphoric acid, and the true 
concentrations ofthe samples were recorded in mgldl. 
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APPENDIX 8: SERUM VITAMIN ANALYSIS 

HPLC method for vitamin A and E analysis243 
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Method for analysis of a-tocopherol, Retinol and ~-carotene 
by HPLC243 
Vitamin Standards were purchased from Anatech and Sigma Aldrich PTY LTD 
respectively. All Standards were kept at -65°C until the stock standards were made 
up. All the standards were made up in a darkened room, and were stored in foil 
covered containers at -65°C until used. All chemicals used in the HPLC analysis were 
ofHPLC grade, and were purchased from Anatech and Merck Chemicals. 
Apparatus 
1. SPSSOO ternary HPLC pump 
2. SP4400 Crom Jet integrator 
3. Supelcosil LC-lS column 
Standards 
Stock Standards: 
The stock standards were of the concentrations below: 
a-carotene IOI-lg/ml 
l3-carotene Img/ml 
Retinyl Palmitate 40mg/ml 
Retinollmg/ml 
Retinyl Acetate Img/ml 
a-tocopherol 500I-lg/ml 
y-tocopherol 500l-lg/ml 
a-tocopherol acetate 10mg/ml 
Therefore we used: 
a-carotene: 
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To make up lOllg/ml: 
Used 5mg standard per 500ml chloroform 
~-carotene: 
To make up Imglml 
Used 25mg standardd per 25ml chloroform 
Retinyl Palmitate: 
To make up 40mglml 
Used lOOmg per 2.5 ml chloroform 
Retinol: 
To make up 1 mg/ml 
Used lOOmg per lOOml ethanol 
Retinyl Acetate: 
To make up 1 mg/ml 
Used lOOmg per lOOml ethanol 
a-tocopberol 
To make up 500uglml 
Used 100mg per 200ml ethanol 
y-tocopberol 
To make up 500ug/ml 

Used 25mg per 50ml ethanol. 

a-tocopberol acetate 
To make up lOmglml 
Used lOOmg per 10ml ethanol 
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Secondary Stock Standards: 
The secondary stock standards were of the concentrations below: 
p-carotene 20jlg/ml 
Retinol 100jlg/ml 
Retinyl acetate 100jlg/ml 
Retinyl palmitate 400jlg/ml 
Therefore we used: 
p-carotene: 

To make up 20jlg/ml 

Took 200ul p-carotene standard. Add 9.8ml ethanol to make up to lOml. 

Retinol: 

To make 100jlg/ml 

Took Iml of retinol standard. Add 9ml ethanol to make up to 10ml 

Retinyl acetate 
To make lOOjlg/ml 
Took Iml ofretinyl acetate standard. Add 9ml ethanol to make up to 10ml. 
Retinyl palmitate 
To make 400jlg/ml 
Took lOOul ofretinyl palmitate STD. Add 9.9ml ethanol to make up to 10ml. 
Working Combined internal Standard 1: 
This standard consisted of: 
O.5jlg/ml Retinyl acetate 
1 jlg/ml. Retinyl palmitate 
25jlg/ml a-tocopherol acetate 
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Therefore add: 
50J.ll Retinyl acetate from secondary stock 
25J.ll a-tocopherol - acetate from stock 
25J.ll ofRetinyl palmitate from secondary stock 
9.9ml Ethanol 
Working combined internal standard 2 
This standard consisted of: 

2Ug/ml Retinyl acetate. 

4J.!g/ml Retinyl palmitate 

I00J.!g/ml a-tocopherol acetate 

Therefore for 10 mls used: 

200J.lI Retinyl acetate secondary standard 

100J.lI Retinyl palmitate secondary standard 

100J.lI a-tocopherol primary standard 

9.6ml ethanol. 

Working combined standard 
The working combined standard contained 
O.2J.lg/ml a-carotene 
50J.lg/ml a-tocopherol 
50J.lg/ml y-tocopherol 
O.4J.lg/ml p-carotene 
2J.lg/ml Retinol 
So took: 
200J.lI of a-carotene from the stock standard 
Iml a-tocopherol from the stock standard 
Iml y-tocopherol from the stock standard 
200J.ll p-carotene from the secondary stock 
200J.ll Retinol from the secondary stock 
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7.4 ml ethanol 
BufIerlMobile Phase 
per litre: 
acetonitrile: 780ml 
Chloroform: 160ml 
2 propanolol35ml 
water: 25ml 
Samples 
1. 	 Place Iml ofserum in 16xlOO culture tube with teflon sealed screw cap. 
2. 	 Slowly add 1ml ofintemal standard 1 to each tube while vortex mixing. 
3. 	 Add 3m Is ofpetroleum ether. 
4. 	 Cap 
5. 	 Vortex mix for 2 minutes. 
6. 	 Centrifuge at SOOg for S minutes 
7. 	 Transfer as much ofupper layer as possible into foil covered lOxlOOmm test tube. 
8. 	 Evaporate to dryness at 37° under stream ofN2. 
9. 	 Reconstitute in 200ul ofmobile phaselbuffer 
Analysis 
1. 	 Set detector at 460nm to measure carotenoids, and at 292nm to measure retinoids 
and tocopherols. 
2. 	 Recorder chart speeds set at O.Scm/minute. 
3. 	 Eluting time 20min 
4. 	 At the beginning of each day's analysis, run the standards on each wavelength 
S. 	 Analyse +/- 40ul ofreconstituted extract 
6. 	 Run each sample in duplicate 
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The standards were defrosted a maximum of 4 times, and then discarded in order to 
prevent degradation. All samples were analysed in duplicate. We had only one 
detector; therefore each sample was run four times - in duplicate on each wavelength. 
Calculations 
area of sample X concentration of standard 
Concentration of 
= 
sample area of standard 
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APPENDIX 9: METHOD FOR QUALITY OF LIFE ANALYSIS 
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Quality of life assessment method 
Pennission was granted to use the SF-36 quality of life form by Prof. John E. Ware. 
With the help of the Statistics department of VCT; we devised our own analysis 
method for the fonn, which approximates the analysis method described in the 
journals, and was used to detennine any differences in quality oflife over the 6 month 
period. This analysis method was used only as a method for detennining improvement 
or deterioration in QOL of our patients over the 6 month supplementation period, and 
not as an indication of QOL in general, or any deficiency in the 10 sections of health 
status that are measured in the form. 
Since the dimension score for the form could have been between 0-100 with a higher 
score showing better health, we transformed all the scores so that health was 
associated with the highest score. This was achieved by the calculations below. Each 
question was calculated separately, and then a total score was calculated from these. 
Please refer to the appendix for the SF-36 quality of life questionnaire. 
If a particular questions' score was lower for better health, these scores were then 
subtracted form a larger no, in order to make the highest score a higher numerical 
value. For example for the fir t question in the questionnaire, which asks how one 
would describe one's health, Excellent scored 1, while poor scored 5. Therefore, it 
makes the healthiest answer a higher numerical value than an unhealthy answer; we 
subtracted the score for 6. In this way the answer excellent, would give a score of 5, 
while the answer poor, would give a score of 1. If a question's score was already in 
this order, just the score was used. The following table shows which questions were 
altered in this way: 
Question no: Total Score equal to: 
1 6-score 
2 6-score 
3a-j Score 
4a-d Score 
5a-c Score 
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6 
7 
8 
Score 
7-score 
6-score 
9a 7-score 
9b Score 
9c Score 
9d 7-score 
ge 7-score 
9f Score 
9g Score 
9h 7-score 
91 Score 
10 Score 
lIa Score 
lIb 6-score 
lIc Score 
lld 6-score 
Therefore, with this method the minimum score that could be obtained was 36, while 

the maximum was 148. Since the SF-36 has a dimension score of 0-100, we 

transformed our data with the formula. 

Total score= (total-36)/113 xlOO so that our final score fell within this range. 
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APPENDIX 10: CASE REPORT FORM FOR 
SUPPLEMENTATION TRIAL·. 
• 

I 
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CRF for subjects on vitamin supplement 
Name: 
No: 
Visit: 1 2 3 4 5 6 
. Date: 
Weight: 
Height: 
• CDAl: 
~ 
Bloods: 
Adverse 
Events: 
Concomtant 
Meds: 
- ......~......... -----------~-----------------
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units %RDA 
Vitamin A 
Vitamin C 
Vitamin E 
· CDAIlHarve,y Bradshaw: 
Blood Results: 
· Haematocrit (%) 
Albumin (g/dl) 
· ESR (mm/hr) 
Vitamin C (mg/dl) 
Retinol (mg/dl) 
B-carotene (mg/dl) 
a.-Tocopherol (mg/dl) 
., 
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Visit 1; Baseline Data 
Date of Diagnosis: 
Extent of Disease: 
Smoking habits: 
Surgery: 
Concomitant medsl 
